Alexander Disease

🏷

Classifications

Harrison's Part

Mechanistic Nosology

🔗

Mappings

MONDO

MONDO:0008752 Alexander disease

Orphanet lists MONDO:0008752 as an exact cross-reference for Alexander disease.

📘

Definitions

1

Orphanet disease definition

Orphanet defines Alexander disease as a rare astrocyte neurodegenerative disorder with type I and type II clinical forms involving macrocephaly, spasticity, ataxia, seizures, regression, and mortality.

CASE_DEFINITION

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"A rare neurodegenerative disorder of the astrocytes comprised of two clinical forms: Alexander disease (AxD) type I and type II manifesting with various degrees of macrocephaly, spasticity, ataxia and seizures and leading to psychomotor regression and death."

Orphanet's definition supports the disease-level clinical framing used in this entry.

👪

Inheritance

1

Autosomal Dominant HP:0000006

Alexander disease is caused by heterozygous gain-of-function mutations in GFAP. The vast majority of cases are de novo. Missense mutations in the coding region of GFAP are found in most cases.

Autosomal dominant inheritance

Show evidence (4 references)

ORPHA:58 SUPPORT Other

"Autosomal dominant"

Orphanet records autosomal dominant inheritance for Alexander disease.

PMID:11567214 SUPPORT Human Clinical

"Heterozygous, de novo mutations in the glial fibrillary acidic protein (GFAP) gene have recently been reported in 12 patients affected by neuropathologically proved Alexander disease"

Confirms de novo, heterozygous GFAP mutations as the genetic basis of infantile Alexander disease.

PMID:11138011 SUPPORT Human Clinical

"Sequence analysis of DNA samples from patients representing different Alexander disease phenotypes revealed that most cases are associated with non-conservative mutations in the coding region of GFAP"

Original discovery paper identifying GFAP mutations as the cause of Alexander disease.

+ 1 more reference

◆

Subtypes

2

Type I (Infantile)

Early-onset form characterized by seizures, macrocephaly, motor delay, encephalopathy, failure to thrive, and typical MRI features including frontal-predominant leukodystrophy. Associated with a nearly 2-fold increase in mortality relative to Type II.

Show evidence (1 reference)

PMID:21917775 SUPPORT Human Clinical

"Type I is characterized by early onset, seizures, macrocephaly, motor delay, encephalopathy, failure to thrive, paroxysmal deterioration, and typical MRI features"

Prust et al. defined Type I AxD based on latent class analysis of 215 patients.

Type II (Juvenile/Adult)

Later-onset form characterized by autonomic dysfunction, ocular movement abnormalities, bulbar symptoms, and atypical MRI features. Brainstem and spinal cord involvement predominate rather than frontal leukodystrophy.

Show evidence (1 reference)

PMID:21917775 SUPPORT Human Clinical

"Type II is characterized by later onset, autonomic dysfunction, ocular movement abnormalities, bulbar symptoms, and atypical MRI features"

Prust et al. defined Type II AxD based on latent class analysis.

?

Discussions and Knowledge Gaps

1

Do STAT3 inhibition, P2Y12-dependent microglial protection, and GFAP antisense suppression reproduce their model-system effects in people with Alexander disease, and which biomarkers reliably demonstrate target engagement?

HUMAN MODEL MISMATCH OPEN gap_axd_preclinical_mechanism_translation

Attached to

pathophysiology#STAT3-Driven GFAP Upregulation pathophysiology#P2Y12-Dependent Protective Microglial Response treatments#Zilganersen (ION373; investigational GFAP antisense oligonucleotide)

Causal STAT3 and P2Y12 evidence is presently derived from mouse models, while GFAP antisense reversal of pathology and functional deficits is preclinical. Human tissue establishes STAT3 activation and human studies establish GFAP as a biomarker and zilganersen as an investigational intervention, but neither proves that these model-derived causal effects translate into clinical benefit.

Show evidence (3 references)

PMID:37048051 SUPPORT Model Organism

"Astrocyte-specific Stat3 knockout in adult mice with existing pathology reversed GFAP accumulation and aggregation."

The intervention supports STAT3 causality in mice, leaving efficacy and causal direction in human disease unresolved.

PMID:37955589 SUPPORT Model Organism

"Clopidogrel significantly exacerbated pathological markers in AxD model mice and attenuated the morphological features of microglia, suggesting that microglia play a protective role against AxD pathology via P2Y12 receptors."

Pharmacologic perturbation supports a protective P2Y12-dependent response in mice, not yet in people with Alexander disease.

clinicaltrials:NCT04849741 SUPPORT Human Clinical

"The purpose of this study is to evaluate the safety and efficacy of zilganersen (ION373) in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD."

The registry establishes human evaluation of zilganersen but does not provide results that resolve translation of preclinical efficacy.

⚙

Pathophysiology

7

Mutant GFAP Proteotoxicity

Gain-of-function mutations in GFAP lead to accumulation of misfolded GFAP protein that forms Rosenthal fibers within astrocytes. These inclusions contain GFAP complexed with small heat shock proteins alphaB-crystallin and HSP27. The aggregation overwhelms the protein quality control machinery. Rosenthal fibers originate as small osmiophilic masses deposited on bundles of intermediate filaments and continue to form over time.

Astrocyte CL:0000127

GFAP hgnc:4235

Protein Aggregation GO:0070841

structural constituent of cytoskeleton GO:0005200

Downstream

Astrocyte Dysfunction GFAP aggregation injures astrocytes, activating glial stress responses that secondarily impair neurons and oligodendrocytes.

White-Matter Oxidative Stress GFAP aggregation and Rosenthal fiber pathology are coupled to oxidative stress responses in white matter.

Show evidence (3 references)

PMID:11138011 SUPPORT Human Clinical

"The pathological hallmark of all forms of Alexander disease is the presence of Rosenthal fibers, cytoplasmic inclusions in astrocytes that contain the intermediate filament protein GFAP in association with small heat-shock proteins"

Defines Rosenthal fibers as the pathological hallmark, composed of GFAP with small heat-shock proteins.

PMID:17498694 SUPPORT Other

"the accumulation of GFAP and the formation of characteristic aggregates, called Rosenthal fibers, (ii) the sequestration of the protein chaperones alpha B-crystallin and HSP27 into Rosenthal fibers, and (iii) the activation of both Jnk and the stress response"

Reviews the multi-step pathogenic mechanism: GFAP accumulation, chaperone sequestration, and stress pathway activation.

PMID:28359321 SUPPORT Model Organism

"RFs appear to originate as small, osmiophilic masses containing both GFAP and alphaB-crystallin deposited on bundles of intermediate filaments"

Mouse model studies reveal the ultrastructural origin of Rosenthal fibers on intermediate filament bundles.

Astrocyte Dysfunction

Mutant GFAP-expressing astrocytes become dysfunctional, with activation of stress response pathways and white matter pathology. Elevated GFAP levels shift GFAP solubility and increase the stress response. Dysfunctional astrocytes fail to support neurons and oligodendrocytes, leading to secondary demyelination and neuronal loss.

Astrocyte CL:0000127 Oligodendrocyte CL:0000128

Myelination GO:0042552 Autophagy GO:0006914

Downstream

P2Y12-Dependent Protective Microglial Response Dysfunctional Alexander disease astrocytes increase extracellular ATP signaling, which is sensed by microglial P2Y12 receptors and elicits a protective response in the mouse model.

STAT3-Driven GFAP Upregulation Astrocyte injury and reactive signaling activate STAT3, which sustains pathological GFAP expression in a feed-forward loop demonstrated in mouse models.

Glutamate Excitotoxicity Toxic mutant GFAP in glia disrupts glial glutamate transport, creating a downstream excitotoxic route to neuronal injury.

Frontal-Predominant Leukoencephalopathy Astrocyte dysfunction disrupts white matter support, contributing to the frontal-predominant leukoencephalopathy of Type I disease.

Macrocephaly Severe early astrocyte and white matter pathology contributes to progressive head enlargement in Type I disease.

Spasticity Astrocyte-driven white matter and corticospinal pathway dysfunction contributes to progressive spasticity.

Dysphagia Brainstem and bulbar network involvement from astrocyte pathology contributes to dysphagia.

Dysarthria Brainstem and bulbar motor pathway involvement from astrocyte pathology contributes to dysarthria.

Ataxia Astrocyte pathology in posterior fossa circuits contributes to ataxia in juvenile and adult-onset disease.

Autonomic Dysfunction Type II brainstem involvement provides the mechanistic route from astrocyte pathology to autonomic dysfunction.

Nystagmus Astrocyte pathology affecting brainstem and cerebellar ocular motor circuits contributes to nystagmus.

Failure to Thrive Severe early astrocyte and white matter pathology contributes to encephalopathy and feeding difficulty, producing failure to thrive in Type I disease.

Intellectual Disability Early astrocyte and white matter pathology impairs neurodevelopmental function in Type I disease.

Global Developmental Delay Early cerebral astrocyte and white matter pathology delays acquisition of developmental milestones in Type I disease.

Hyperreflexia Astrocyte-driven corticospinal pathway dysfunction produces pyramidal signs such as hyperreflexia.

Clonus Corticospinal pathway involvement produces clonus as part of the pyramidal-sign phenotype.

Abnormal Pyramidal Sign Astrocyte and white matter pathology affecting corticospinal tracts produces abnormal pyramidal signs.

Megalencephaly Type I astrocyte and white matter pathology contributes to brain enlargement captured as megalencephaly.

Frontal Bossing Cranial enlargement in Type I disease contributes to frontal bossing.

Large Face The Type I cranial enlargement phenotype is associated with a large-face craniofacial appearance.

Abnormality of Speech or Vocalization Astrocyte pathology affecting bulbar, cerebellar, and brainstem circuits contributes to abnormal speech or vocalization.

Nausea and Vomiting Brainstem and autonomic involvement provides the route to nausea and vomiting in later-onset disease.

Sleep Abnormality Diffuse astrocyte-driven neurologic dysfunction likely contributes to sleep disturbance, although the specific sleep-circuit intermediates are not yet resolved.

Scoliosis Chronic motor pathway involvement in later-onset disease contributes to scoliosis.

Show evidence (3 references)

PMID:17065456 SUPPORT Model Organism

"further elevation of GFAP via crosses to GFAP transgenic animals leads to a shift in GFAP solubility, an increased stress response, and ultimately death"

Mouse model demonstrates dose-dependent GFAP toxicity with solubility shift and lethal stress response.

PMID:29226998 SUPPORT Model Organism

"A key feature of pathogenesis is overexpression and accumulation of GFAP, with formation of characteristic cytoplasmic aggregates known as Rosenthal fibers"

Confirms GFAP overexpression and accumulation as central to pathogenesis.

PMID:21414908 SUPPORT Model Organism

"Both protein aggregation and oxidative stress contribute to activation of a robust autophagic response in glia"

Drosophila model shows that GFAP aggregation and oxidative stress activate autophagy in glial cells.

White-Matter Oxidative Stress

GFAP mutations induce an antioxidant/oxidative stress response in white matter, with iron accumulation in corpus callosum. Knock-in mice with GFAP mutations show a distinct pattern of stress response gene induction particularly prominent in white matter regions.

Astrocyte CL:0000127

Oxidative Stress Response GO:0006979

Downstream

Oxidative GFAP Crosslinking Oxidant stress modifies GFAP and promotes disulfide-linked oligomerization, closing a model-supported cycle between mutant GFAP proteotoxicity and oxidative injury.

Frontal-Predominant Leukoencephalopathy Oxidative stress in white matter regions contributes to the leukodystrophy phenotype.

Seizures GFAP mutant white matter stress and gliosis increase seizure susceptibility.

Show evidence (1 reference)

PMID:17065456 SUPPORT Model Organism

"when crossed with an antioxidant response element reporter line, the mutant mice show a distinct pattern of reporter-gene induction that is especially prominent in the corpus callosum, and histochemical staining reveals accumulation of iron in the same region"

GFAP mutant mice show oxidative stress response and iron accumulation in white matter.

Glutamate Excitotoxicity

Dysfunctional astrocytes in Alexander disease show impaired glutamate uptake via astrocytic transporters, leading to toxic accumulation of extracellular glutamate. This non-cell-autonomous mechanism causes neuronal apoptosis dependent on glial glutamate transport.

Astrocyte CL:0000127 Neuron CL:0000540

Neurotransmitter Transport GO:0006836

Downstream

Seizures Impaired glial glutamate handling provides a plausible excitotoxic route to seizures.

Psychomotor Regression Non-cell-autonomous neuronal apoptosis contributes to progressive developmental regression and neurologic decline.

EEG Abnormality Glutamate-mediated hyperexcitability and seizures provide a route to abnormal EEG findings.

Show evidence (1 reference)

PMID:21414908 SUPPORT Model Organism

"Toxicity of mutant GFAP to glial cells induces a non-cell-autonomous stress response and subsequent apoptosis in neurons, which is dependent on glial glutamate transport"

Drosophila model demonstrates that mutant GFAP toxicity to glia causes neuronal apoptosis via glutamate-dependent mechanism.

Oxidative GFAP Crosslinking

Disease-associated GFAP mutations promote pathological post-translational modifications including aberrant disulfide cross-linking (particularly cysteine-generating mutations like R239C) and ubiquitination. These modifications yield high-molecular-weight insoluble GFAP species that contribute to Rosenthal fiber formation and resist proteolytic clearance.

Astrocyte CL:0000127

GFAP hgnc:4235

Protein Ubiquitination GO:0016567

structural constituent of cytoskeleton GO:0005200

Downstream

Mutant GFAP Proteotoxicity Oxidation, crosslinking, and ubiquitination decrease GFAP solubility and promote Rosenthal fiber aggregation.

Show evidence (3 references)

PMID:38782207 SUPPORT Human Clinical

"We found high molecular weight GFAP species in the RFs of AxD brains, indicating abnormal GFAP crosslinking as a prominent pathological feature of this disease"

Analysis of AxD patient brain tissue identifies aberrant GFAP crosslinking as a key pathological modification.

PMID:38782207 SUPPORT Human Clinical

"we found GFAP was ubiquitinated in RFs of AxD patients"

Patient brain Rosenthal fibers show GFAP ubiquitination, supporting this modification as part of human aggregation pathology.

PMID:41830670 SUPPORT In Vitro

"Formation of disulfide bonds, some of which involved mutation-introduced cysteine residues, results in GFAP oligomerization in vitro and in cells."

Cell and in-vitro experiments directly show disulfide-linked GFAP oligomerization, including crosslinks involving mutation-introduced cysteines.

STAT3-Driven GFAP Upregulation

Activated STAT3 sustains pathological GFAP expression in Alexander disease astrocytes. Astrocyte-specific Stat3 deletion after pathology was established reversed GFAP accumulation and aggregation in mice, identifying a modifiable feed-forward driver rather than merely a marker of reactive gliosis.

Astrocyte CL:0000127

STAT3 hgnc:11364

Downstream

Mutant GFAP Proteotoxicity STAT3-dependent elevation of GFAP increases the protein burden that accumulates and aggregates in Alexander disease astrocytes.

Show evidence (2 references)

PMID:37048051 SUPPORT Human Clinical

"In this report, we show that STAT3 is also activated in the human disease."

Patient tissue establishes that STAT3 activation is present in human Alexander disease, while not by itself establishing causal direction.

PMID:37048051 SUPPORT Model Organism

"Astrocyte-specific Stat3 knockout in adult mice with existing pathology reversed GFAP accumulation and aggregation."

Conditional knockout after disease pathology had developed provides intervention evidence that STAT3 drives GFAP accumulation in the mouse model.

P2Y12-Dependent Protective Microglial Response

Microglia detect excess extracellular ATP arising from dysfunctional Alexander disease astrocytes through P2Y12 receptors. Pharmacologic P2Y12 blockade worsened pathological markers in mice, supporting a compensatory, protective microglial response rather than a disease-driving inflammatory step.

Microglial cell CL:0000129

Show evidence (1 reference)

PMID:37955589 SUPPORT Model Organism

"Clopidogrel significantly exacerbated pathological markers in AxD model mice and attenuated the morphological features of microglia, suggesting that microglia play a protective role against AxD pathology via P2Y12 receptors."

P2Y12 inhibition worsened disease-model pathology, supporting a protective role for P2Y12-dependent microglial activity.

✶

Histopathology

1

Astrocytic Rosenthal fibers

Cytoplasmic astrocyte inclusions containing GFAP and small heat-shock proteins are the pathological hallmark of all forms, but their presence should be interpreted with clinical, imaging, and molecular findings.

Show evidence (1 reference)

PMID:11138011 SUPPORT Human Clinical

"The pathological hallmark of all forms of Alexander disease is the presence of Rosenthal fibers, cytoplasmic inclusions in astrocytes that contain the intermediate filament protein GFAP in association with small heat-shock proteins"

Human neuropathology establishes the characteristic inclusion, its astrocytic location, and its composition.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

24

Digestive 2

Dysphagia FREQUENT HP:0002015

Show evidence (2 references)

ORPHA:58 SUPPORT Other

"HP:0002015 | Dysphagia | Frequent (79-30%)"

Orphanet's curated HPO table classifies dysphagia as frequent in Alexander disease.

PMID:21917775 SUPPORT Human Clinical

"Type II is characterized by later onset, autonomic dysfunction, ocular movement abnormalities, bulbar symptoms, and atypical MRI features"

Dysphagia is part of the bulbar symptom complex defining Type II AxD.

Nausea and Vomiting VERY_FREQUENT HP:0002017

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"HP:0002017 | Nausea and vomiting | Very frequent (99-80%)"

Orphanet's curated HPO table classifies nausea and vomiting as very frequent in Alexander disease.

Eye 1

Nystagmus FREQUENT HP:0000639

Show evidence (2 references)

ORPHA:58 SUPPORT Other

"HP:0000639 | Nystagmus | Frequent (79-30%)"

Orphanet's curated HPO table classifies nystagmus as frequent in Alexander disease.

PMID:21917775 SUPPORT Human Clinical

"Type II is characterized by later onset, autonomic dysfunction, ocular movement abnormalities, bulbar symptoms, and atypical MRI features"

Ocular movement abnormalities including nystagmus are characteristic of Type II Alexander disease.

Head and Neck 2

Macrocephaly VERY_FREQUENT HP:0000256

Show evidence (4 references)

ORPHA:58 SUPPORT Other

"HP:0000256 | Macrocephaly | Very frequent (99-80%)"

Orphanet's curated HPO table classifies macrocephaly as very frequent in Alexander disease.

PMID:11138011 SUPPORT Human Clinical

"Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures and psychomotor retardation"

Macrocephaly is a cardinal feature of infantile Alexander disease.

PMID:21917775 SUPPORT Human Clinical

"Type I is characterized by early onset, seizures, macrocephaly, motor delay, encephalopathy, failure to thrive, paroxysmal deterioration, and typical MRI features"

Macrocephaly is a defining feature of Type I Alexander disease.

+ 1 more reference

Frontal Bossing VERY_FREQUENT HP:0002007

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"HP:0002007 | Frontal bossing | Very frequent (99-80%)"

Orphanet's curated HPO table classifies frontal bossing as very frequent in Alexander disease.

Musculoskeletal 2

Spasticity VERY_FREQUENT HP:0001257

Show evidence (2 references)

ORPHA:58 SUPPORT Other

"HP:0001257 | Spasticity | Very frequent (99-80%)"

Orphanet's curated HPO table classifies spasticity as very frequent in Alexander disease.

PMID:11138011 SUPPORT Human Clinical

"patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course"

Spasticity is a characteristic feature of juvenile/adult Alexander disease.

Scoliosis VERY_FREQUENT HP:0002650

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"HP:0002650 | Scoliosis | Very frequent (99-80%)"

Orphanet's curated HPO table classifies scoliosis as very frequent in Alexander disease.

Nervous System 12

Global Developmental Delay VERY_FREQUENT HP:0001263

Show evidence (1 reference)

PMID:37920915 SUPPORT Human Clinical

"Developmental delay was the earliest and most prevalent symptom"

The 51-person cerebral-phenotype cohort identifies developmental delay as the earliest and most prevalent of the classic pediatric features.

Frontal-Predominant Leukoencephalopathy HP:0002352

Show evidence (2 references)

PMID:11138011 SUPPORT Human Clinical

"Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures and psychomotor retardation"

Leukoencephalopathy is a defining feature of infantile Alexander disease.

PMID:21917775 SUPPORT Human Clinical

"Type I is characterized by early onset, seizures, macrocephaly, motor delay, encephalopathy, failure to thrive, paroxysmal deterioration, and typical MRI features"

Typical MRI features including frontal-predominant leukodystrophy define Type I.

Seizures VERY_FREQUENT HP:0001250

Show evidence (4 references)

ORPHA:58 SUPPORT Other

"HP:0001250 | Seizure | Very frequent (99-80%)"

Orphanet's curated HPO table classifies seizures as very frequent in Alexander disease.

PMID:11138011 SUPPORT Human Clinical

"Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures and psychomotor retardation"

Seizures are a primary clinical feature of infantile Alexander disease.

PMID:17065456 SUPPORT Model Organism

"The mutant mice have a normal lifespan and show no overt behavioral defects, but are more susceptible to kainate-induced seizures"

GFAP mutant knock-in mice recapitulate seizure susceptibility.

+ 1 more reference

Dysarthria FREQUENT HP:0001260

Show evidence (2 references)

ORPHA:58 SUPPORT Other

"HP:0001260 | Dysarthria | Frequent (79-30%)"

Orphanet's curated HPO table classifies dysarthria as frequent in Alexander disease.

PMID:11138011 SUPPORT Human Clinical

"patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course"

Dysarthria is part of the bulbar signs characterizing juvenile/adult Alexander disease.

Ataxia FREQUENT HP:0001251

Show evidence (2 references)

ORPHA:58 SUPPORT Other

"HP:0001251 | Ataxia | Frequent (79-30%)"

Orphanet's curated HPO table classifies ataxia as frequent in Alexander disease.

PMID:11138011 SUPPORT Human Clinical

"patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity"

Ataxia is characteristic of juvenile/adult Alexander disease.

Psychomotor Regression OCCASIONAL Developmental regression HP:0002376

Show evidence (2 references)

ORPHA:58 SUPPORT Other

"HP:0002376 | Developmental regression | Occasional (29-5%)"

Orphanet's curated HPO table classifies developmental regression as occasional in Alexander disease.

PMID:11138011 SUPPORT Human Clinical

"Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures and psychomotor retardation, leading to death usually within the first decade"

Psychomotor retardation with progressive decline is a hallmark of infantile Alexander disease.

Autonomic Dysfunction OCCASIONAL Abnormal autonomic nervous system physiology HP:0012332

Show evidence (2 references)

ORPHA:58 SUPPORT Other

"HP:0012332 | Abnormal autonomic nervous system physiology | Occasional (29-5%)"

Orphanet's curated HPO table classifies abnormal autonomic nervous system physiology as occasional in Alexander disease.

PMID:21917775 SUPPORT Human Clinical

"Type II is characterized by later onset, autonomic dysfunction, ocular movement abnormalities, bulbar symptoms, and atypical MRI features"

Autonomic dysfunction is a defining feature of Type II Alexander disease.

Intellectual Disability VERY_FREQUENT HP:0001249

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"HP:0001249 | Intellectual disability | Very frequent (99-80%)"

Orphanet's curated HPO table classifies intellectual disability as very frequent in Alexander disease.

Hyperreflexia VERY_FREQUENT HP:0001347

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"HP:0001347 | Hyperreflexia | Very frequent (99-80%)"

Orphanet's curated HPO table classifies hyperreflexia as very frequent in Alexander disease.

Abnormality of Speech or Vocalization VERY_FREQUENT Abnormal speech pattern HP:0002167

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"HP:0002167 | Abnormality of speech or vocalization | Very frequent (99-80%)"

Orphanet's curated HPO table classifies abnormality of speech or vocalization as very frequent in Alexander disease.

EEG Abnormality VERY_FREQUENT HP:0002353

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"HP:0002353 | EEG abnormality | Very frequent (99-80%)"

Orphanet's curated HPO table classifies EEG abnormality as very frequent in Alexander disease.

Sleep Abnormality VERY_FREQUENT Sleep disturbance HP:0002360

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"HP:0002360 | Sleep abnormality | Very frequent (99-80%)"

Orphanet's curated HPO table classifies sleep abnormality as very frequent in Alexander disease.

Growth 1

Failure to Thrive VERY_FREQUENT HP:0001508

Show evidence (2 references)

ORPHA:58 SUPPORT Other

"HP:0001508 | Failure to thrive | Very frequent (99-80%)"

Orphanet's curated HPO table classifies failure to thrive as very frequent in Alexander disease.

PMID:21917775 SUPPORT Human Clinical

"Type I is characterized by early onset, seizures, macrocephaly, motor delay, encephalopathy, failure to thrive, paroxysmal deterioration, and typical MRI features"

Failure to thrive is a defining feature of Type I Alexander disease.

Other 4

Megalencephaly VERY_FREQUENT HP:0001355

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"HP:0001355 | Megalencephaly | Very frequent (99-80%)"

Orphanet's curated HPO table classifies megalencephaly as very frequent in Alexander disease.

Clonus VERY_FREQUENT HP:0002169

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"HP:0002169 | Clonus | Very frequent (99-80%)"

Orphanet's curated HPO table classifies clonus as very frequent in Alexander disease.

Abnormal Pyramidal Sign VERY_FREQUENT HP:0007256

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"HP:0007256 | Abnormal pyramidal sign | Very frequent (99-80%)"

Orphanet's curated HPO table classifies abnormal pyramidal sign as very frequent in Alexander disease.

Large Face VERY_FREQUENT HP:0100729

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"HP:0100729 | Large face | Very frequent (99-80%)"

Orphanet's curated HPO table classifies large face as very frequent in Alexander disease.

🧬

Genetic Associations

1

GFAP Gain-of-Function Mutations (Causative)

Gene: GFAP hgnc:4235

Autosomal Dominant

Show evidence (5 references)

CGGV:assertion_1da6d658-360e-4097-95a9-0b6838638e31-2024-01-10T170000.000Z SUPPORT Other

ClinGen classifies the GFAP-Alexander disease gene-disease relationship as definitive with autosomal dominant inheritance.

PMID:11138011 SUPPORT Human Clinical

"Alexander disease therefore represents the first example of a primary genetic disorder of astrocytes, one of the major cell types in the vertebrate CNS"

Landmark paper establishing GFAP mutations as causative for Alexander disease.

PMID:21917775 SUPPORT Human Clinical

"R79 and R239 GFAP mutations were most common (16.6% and 20.3% of all cases, respectively). These common mutations predicted distinct clinical outcomes, with R239 predicting the most aggressive course"

Identifies mutation hotspots and genotype-phenotype correlations in a large cohort.

+ 2 more references

Variants (3)

GFAP R79 missense hotspot Pathogenic

Gene: GFAP hgnc:4235 missense

Recurrent heterozygous GFAP R79 substitutions, especially R79H, are a common Alexander disease hotspot. They enter the canonical toxic gain-of-function path from mutant GFAP through Rosenthal fiber formation, astrocyte dysfunction, white matter injury, and subtype-specific neurologic phenotypes.

Functional effects

toxic gain-of-function

Missense substitution in the GFAP rod domain promotes dominant astrocyte intermediate-filament pathology.

Show evidence (2 references)

PMID:11567214 SUPPORT Human Clinical

"Nine patients carried arginine mutations (four had R79H; four had R239C; and one had R239H)"

Documents R79H among recurrent arginine hotspot mutations in infantile Alexander disease.

PMID:21917775 SUPPORT Human Clinical

"R79 and R239 GFAP mutations were most common (16.6% and 20.3% of all cases, respectively)"

Large cohort analysis identifies R79 as one of the two most common GFAP mutation sites.

GFAP R239 missense hotspot Pathogenic

Gene: GFAP hgnc:4235 missense

Recurrent heterozygous GFAP R239 substitutions, including R239C and R239H, are the most common hotspot group and are associated with a more aggressive clinical course, while R239H has earlier onset than R239C. R239 variants follow the toxic GFAP path through aggregation, Rosenthal fibers, astrocyte dysfunction, and severe Type I-weighted neurologic phenotypes.

Functional effects

toxic gain-of-function

Missense substitution at GFAP Arg239 promotes dominant GFAP aggregation and severe astrocyte pathology.

Show evidence (4 references)

PMID:11567214 SUPPORT Human Clinical

"Nine patients carried arginine mutations (four had R79H; four had R239C; and one had R239H)"

Identifies R239C and R239H among recurrent GFAP hotspot mutations.

PMID:21917775 SUPPORT Human Clinical

"These common mutations predicted distinct clinical outcomes, with R239 predicting the most aggressive course"

Links the R239 hotspot to the most aggressive clinical trajectory.

PMID:40520824 SUPPORT Human Clinical

"Pairwise comparison results found that R239H was associated with significantly earlier onsets than R239C."

A newer variant-level analysis qualifies the hotspot association by demonstrating heterogeneity among R239 substitutions.

+ 1 more reference

GFAP cysteine-generating aggregation-prone variants Pathogenic

Gene: GFAP hgnc:4235 missense

Cysteine-generating GFAP variants, represented in Alexander disease cohorts by R239C and R88C, provide a variant-specific path into abnormal GFAP oxidation and crosslinking before aggregate and Rosenthal fiber formation.

Functional effects

abnormal GFAP oxidation and crosslinking

Cysteine-generating substitutions promote GFAP crosslinking, defective assembly, and decreased filament solubility.

Show evidence (2 references)

PMID:11567214 SUPPORT Human Clinical

"mutations, of which two affect arginine (2R88C and 1R88S) and two affect nonarginine residues (1L76F and 1N77Y)"

Clinical cohort identifies R88C as another cysteine-generating GFAP arginine substitution.

PMID:38782207 SUPPORT In Vitro

"In vitro and cell-based studies demonstrate that cystine-generating mutations promote GFAP crosslinking by cysteine-dependent oxidation"

Functional evidence provides a variant-specific mechanism from cysteine-generating GFAP mutations to crosslinking and aggregation.

🗃️

External Assertions

1

Orphanet Alexander disease record

Orphanet structured disease record ORPHA:58

Orphanet curates ORPHA:58 as the Alexander disease disorder record and provides exact cross-references to MONDO:0008752, OMIM:203450, and ICD-11:8A44.2, with a narrower ICD-10:G93.8 cross-reference.

Show evidence (5 references)

ORPHA:58 SUPPORT Other

"ORPHA:58 Alexander disease"

The Orphanet structured record heading identifies ORPHA:58 as the Alexander disease record.

ORPHA:58 SUPPORT Other

"MONDO:0008752 | Exact"

Orphanet maps ORPHA:58 exactly to the MONDO disease identifier used by this entry.

ORPHA:58 SUPPORT Other

"OMIM:203450 | Exact"

Orphanet lists OMIM:203450 as an exact external cross-reference for Alexander disease.

+ 2 more references

💊

Medical Actions

2

Supportive Care

Action: Supportive Care NCIT:C15747

Management is primarily supportive, including anti-epileptic drugs for seizures, physical therapy, and nutritional support. No disease-modifying therapy is currently approved.

Show evidence (1 reference)

PMID:20301351 SUPPORT Human Clinical

"Treatment is supportive and focuses on management by multidisciplinary specialists to manage general care, feeding, and nutrition; anti-seizure medication; physical and occupational therapy; speech and language therapy; and appropriate educational services."

GeneReviews directly supports multidisciplinary symptomatic management and the specific care domains summarized here.

Zilganersen (ION373; investigational GFAP antisense oligonucleotide)

Action: antisense oligonucleotide therapy Ontology label: Pharmacotherapy NCIT:C15986

Agent: Zilganersen NCIT:C186394

Antisense oligonucleotides targeting GFAP mRNA have shown efficacy in mouse and rat models, achieving near-complete elimination of GFAP protein with reversal of Rosenthal fibers, white matter deficits, and motor impairment. Zilganersen is being evaluated in humans, but the trial registry does not establish clinical efficacy.

Mechanism Target:

INHIBITS Mutant GFAP Proteotoxicity — GFAP-targeted antisense oligonucleotides lower GFAP protein, interrupting the aggregation/Rosenthal fiber mechanism upstream of astrocyte stress and white matter injury.

Show evidence (1 reference)

PMID:29226998 SUPPORT Model Organism

"Nearly complete and long-lasting elimination of GFAP occurred in brain and spinal cord following single bolus intracerebroventricular injections, with a striking reversal of Rosenthal fibers and downstream markers of microglial and other stress-related responses"

ASO-mediated GFAP suppression targets the upstream aggregation mechanism and reverses downstream stress markers in animal models.

Show evidence (4 references)

PMID:29226998 SUPPORT Model Organism

"Nearly complete and long-lasting elimination of GFAP occurred in brain and spinal cord following single bolus intracerebroventricular injections, with a striking reversal of Rosenthal fibers and downstream markers of microglial and other stress-related responses"

Antisense oligonucleotides effectively suppress GFAP and reverse pathology in AxD mouse models.

PMID:29226998 SUPPORT Model Organism

"GFAP protein was also cleared from cerebrospinal fluid, demonstrating its potential utility as a biomarker in future clinical applications"

CSF GFAP clearance provides a potential biomarker for monitoring treatment response.

PMID:34788075 SUPPORT Model Organism

"a single treatment with Gfap-targeted ASO provides long-lasting suppression, reverses GFAP pathology, and, depending on age of treatment, prevents or mitigates white matter deficits and motor impairment"

Rat model with myelin pathology demonstrates ASO therapy can both prevent and reverse disease features.

+ 1 more reference

🔬

Biochemical Markers

1

Cerebrospinal-fluid and plasma GFAP (INCREASED)

Context: Elevated across the clinical spectrum; concentrations are higher in the cerebral phenotype and rise over time in young children.

Pathograph Readouts

Readout Of Mutant GFAP Proteotoxicity Positive Diagnostic

Elevated soluble GFAP in CSF or plasma reports the abnormal GFAP burden but is not independently diagnostic of Alexander disease.

Show evidence (1 reference)

PMID:41513585 SUPPORT Human Clinical

"GFAP concentrations were significantly elevated at baseline in both AxD CSF (N = 44) compared to controls (N = 46, p < 0.0001) and AxD plasma (N = 96) compared to other leukodystrophy plasma controls (N = 67, p < 0.0001)."

The human cohort directly links elevated CSF and plasma GFAP to Alexander disease relative to control groups.

Show evidence (2 references)

PMID:41513585 SUPPORT Human Clinical

"GFAP concentrations are higher in the cerebral phenotype and increase over time in young children."

This supports phenotype and age dependence, preventing overgeneralization of a single reference range across the disease spectrum.

PMID:38558318 SUPPORT Human Clinical

"Here, we report that GFAP is elevated in plasma of all age groups afflicted by AxD, including those with adult onset."

The plasma study supports biomarker elevation across age groups, including adult-onset disease.

🔬

Diagnosis

1

Clinical and MRI assessment with molecular confirmation

Suggestive age-dependent clinical and neuroimaging findings prompt testing; identification of a heterozygous pathogenic GFAP variant establishes the diagnosis.

Show evidence (2 references)

PMID:20301351 SUPPORT Human Clinical

"The diagnosis of Alexander disease is established in a proband with suggestive clinical and neuroimaging findings and a heterozygous pathogenic variant in GFAP identified by molecular genetic testing."

GeneReviews defines the integrated clinical, imaging, and molecular route to diagnosis and the definitive molecular finding.

PMID:21533827 SUPPORT Human Clinical

"To ensure correct diagnosis of AxD, the physician should understand the importance of the process of GFAP genetic testing, which provides definitive diagnosis."

The nationwide diagnostic guideline independently identifies GFAP testing as definitive.

🩻

Imaging Findings

3

Frontal-predominant cerebral white-matter abnormalities on MRI

Brain MRI commonly shows frontal-predominant cerebral white-matter abnormalities in early-onset Alexander disease.

Mri Diagnostic Type I Characteristic cerebral pattern in infantile and juvenile disease; molecular confirmation remains definitive.

Leukoencephalopathy HP:0002352 brain white matter UBERON:0003544 Leukoencephalopathy HP:0002352

Show evidence (1 reference)

PMID:21533827 SUPPORT Human Clinical

"The main characteristics of infantile and juvenile AxD include delayed psychomotor development or mental retardation, convulsions, macrocephaly, and predominant cerebral white matter abnormalities in the frontal lobe on brain MRI."

The nationwide survey directly supports the frontal-predominant cerebral MRI pattern in early-onset disease.

Medulla-oblongata signal abnormality or atrophy on MRI

Adult Alexander disease commonly shows medulla-oblongata signal abnormality or atrophy on MRI.

Mri Diagnostic Type II One component of the characteristic adult bulbospinal pattern; molecular confirmation remains definitive.

medulla oblongata UBERON:0001896

Show evidence (1 reference)

PMID:21533827 SUPPORT Human Clinical

"The main characteristics of adult AxD include bulbar signs, muscle weakness with hyperreflexia, and signal abnormalities and/or atrophy of medulla oblongata and cervical spinal cord on MRI."

The nationwide survey directly supports medulla-oblongata signal abnormality or atrophy as part of the adult bulbospinal MRI pattern.

Cervical spinal-cord signal abnormality or atrophy on MRI

Adult Alexander disease commonly shows cervical spinal-cord signal abnormality or atrophy on MRI.

Mri Diagnostic Type II One component of the characteristic adult bulbospinal pattern; molecular confirmation remains definitive.

cervical spinal cord UBERON:0002726

Show evidence (1 reference)

PMID:21533827 SUPPORT Human Clinical

"The main characteristics of adult AxD include bulbar signs, muscle weakness with hyperreflexia, and signal abnormalities and/or atrophy of medulla oblongata and cervical spinal cord on MRI."

The nationwide survey directly supports cervical spinal-cord signal abnormality or atrophy as part of the adult bulbospinal MRI pattern.

📈

Progression

1

Onset

Age: All ages

Orphanet classifies Alexander disease onset as possible at all ages.

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"Age of onset: All ages"

Orphanet's natural-history section records all-age onset for Alexander disease.

📊

Prevalence

2

Japan (Orphanet annual incidence)

Annual Incidence ≤0.1 per 100,000 <1 in 1,000,000

Orphanet reports an annual-incidence class below 1 per 1,000,000 in Japan.

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"<1 / 1 000 000 | Japan | Annual incidence | PMID:21533827,EXPERT"

The Orphanet epidemiology table reports the annual-incidence class for Alexander disease in Japan.

Worldwide (Orphanet point prevalence)

Point Prevalence Unknown Unknown

Orphanet records the worldwide point-prevalence class as unknown.

Show evidence (1 reference)

ORPHA:58 SUPPORT Other

"Unknown | Worldwide | Point prevalence | ORPHANET"

The Orphanet epidemiology table records worldwide point prevalence as unknown.

📊

Related Datasets

2

Aberrant neurodevelopment in human iPS cell-derived models of Alexander disease. geo:GSE261158

human BULK RNA SEQ n=10

PMID:39308436

Identified by GEO DataSets index search for Alexander Disease (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

Gene expression changes associated with Alexander disease (AxD) geo:GSE116327

We use human induced pluripotent stem cell (hiPSC)-derived astrocytes and post-mortem human brain tissues to study gene expression changes associated with AxD

human BULK RNA SEQ n=12

Identified by GEO DataSets index search for Alexander Disease (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

🔬

Clinical Trials

2

NCT04849741 PHASE_III ACTIVE_NOT_RECRUITING

Intrathecal zilganersen (ION373) interventional study evaluating safety, pharmacokinetics, pharmacodynamics, and whether gross motor function improves or stabilizes. The ClinicalTrials.gov record was checked on 2026-08-04; the registry describes evaluation and does not report efficacy results.

Show evidence (1 reference)

clinicaltrials:NCT04849741 SUPPORT Human Clinical

"The purpose of this study is to evaluate the safety and efficacy of zilganersen (ION373) in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD."

The trial registry supports the investigational agent, disease population, and motor-function objective without supporting clinical efficacy.

NCT02714764 NOT_APPLICABLE RECRUITING

Observational natural-history study collecting functional outcomes and CSF and blood GFAP measurements to define outcome metrics for future Alexander disease treatment trials. Status was checked on 2026-08-04.

Show evidence (1 reference)

clinicaltrials:NCT02714764 SUPPORT Human Clinical

"The purpose of this study is to define the natural history of Alexander Disease, a leukodystrophy that causes neurological dysfunction. Investigators will obtain clinical outcome assessments to measure how the disease affects a patient's gross motor, fine motor, speech and language function,..."

The registry directly supports the observational outcome domains and GFAP specimen collection used for trial-readiness research.

🐁

Animal Models

3

Gfap R76H/+ and Gfap R236H/+ knock-in Mus musculus

Knock-in mice carrying GFAP-R76H and -R236H mutations (homologous to human R79H and R239H) develop Rosenthal fibers in hippocampus, corpus callosum, olfactory bulbs, subpial, and periventricular regions. Mice show elevated GFAP, white matter stress response, and increased seizure susceptibility but have normal lifespan, resembling adult-onset disease.

Species

Mus musculus

Genotype

Gfap R76H/+ and Gfap R236H/+ knock-in

Show evidence (2 references)

PMID:17065456 SUPPORT Model Organism

"mice with GFAP-R76H and -R236H mutations develop Rosenthal fibers, the hallmark protein aggregates observed in astrocytes in AxD, in the hippocampus, corpus callosum, olfactory bulbs, subpial, and periventricular regions"

Knock-in mice recapitulate Rosenthal fiber formation in disease-relevant brain regions.

PMID:17065456 SUPPORT Model Organism

"These studies provide formal proof linking GFAP mutations with Rosenthal fibers and oxidative stress, and correlate gliosis and GFAP protein levels to the severity of the disease"

Provides formal proof of causality between GFAP mutations and Rosenthal fiber pathology.

Gfap R239H/+ knock-in Rattus norvegicus

Knock-in rat carrying the GFAP R239H mutation exhibits hallmark pathology including Rosenthal fibers, widespread astrogliosis, and white matter deficits. Animals develop normally in early postnatal weeks but fail to thrive after weaning, developing severe motor deficits with approximately 14% dying between 6 and 12 weeks. This model recapitulates myelin pathology and motor impairment seen in human disease, unlike the milder mouse models.

Species

Rattus norvegicus

Genotype

Gfap R239H/+ knock-in

Show evidence (2 references)

PMID:34788075 SUPPORT Model Organism

"we introduce a rat model of AxD that exhibits hallmark pathology with GFAP aggregation in the form of Rosenthal fibers, widespread astrogliosis, and white matter deficits"

Rat AxD model with clinically relevant myelin pathology and motor impairment.

PMID:34788075 SUPPORT Model Organism

"These animals develop normally during the first postnatal weeks but fail to thrive after weaning and develop severe motor deficits as they mature, with about 14% dying of unknown cause between 6 and 12 weeks of age"

Characterizes the time course of disease progression in the rat model.

Glial expression of human GFAP R79H and R239H Drosophila melanogaster

Transgenic Drosophila expressing disease-linked mutant human GFAP in fly glia develop inclusions bearing hallmarks of authentic Rosenthal fibers. The model demonstrates non-cell-autonomous neurodegeneration mediated by protein aggregation and oxidative stress, with neuronal apoptosis dependent on glial glutamate transport.

Species

Drosophila melanogaster

Genotype

Glial expression of human GFAP R79H and R239H

Show evidence (2 references)

PMID:21414908 SUPPORT Model Organism

"We find aggregation of mutant human GFAP into inclusions bearing the hallmarks of authentic Rosenthal fibers"

Drosophila model recapitulates Rosenthal fiber formation from mutant human GFAP.

PMID:21414908 SUPPORT Model Organism

"Toxicity of mutant GFAP to glial cells induces a non-cell-autonomous stress response and subsequent apoptosis in neurons, which is dependent on glial glutamate transport"

Demonstrates non-cell-autonomous neurodegeneration mechanism via glutamate-dependent pathway.

{ }

Source YAML

click to show

name: Alexander Disease
creation_date: "2026-03-14T00:00:00Z"
category: Mendelian
description: >
  Alexander disease is a rare, progressive neurodegenerative disorder caused by
  dominant gain-of-function mutations in GFAP (glial fibrillary acidic protein),
  the major intermediate filament of astrocytes. It is the only known primary
  genetic disorder of astrocytes. The hallmark pathological feature is the
  accumulation of Rosenthal fibers - cytoplasmic inclusions composed of GFAP
  aggregates complexed with small heat shock proteins alphaB-crystallin and HSP27
  -
  within astrocytes. The disease presents along a clinical spectrum from a severe
  infantile form (Type I) with macrocephaly, seizures, and frontal leukodystrophy
  to milder adult-onset forms (Type II) with bulbar symptoms, autonomic dysfunction,
  and atypical MRI features.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
  mechanistic_category:
  - classification_value: intermediate filament disease
  - classification_value: proteotoxic disease

disease_term:
  preferred_term: Alexander disease
  term:
    id: MONDO:0008752
    label: Alexander disease
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0008752
      label: Alexander disease
    mapping_predicate: skos:exactMatch
    mapping_source: ORPHA:58
    mapping_justification: Orphanet lists MONDO:0008752 as an exact cross-reference for Alexander disease.
    consistency:
    - reference: ORPHA:58
      consistent: CONSISTENT
      notes: "MONDO:0008752 | Exact"
definitions:
- name: Orphanet disease definition
  definition_type: CASE_DEFINITION
  description: >
    Orphanet defines Alexander disease as a rare astrocyte neurodegenerative
    disorder with type I and type II clinical forms involving macrocephaly,
    spasticity, ataxia, seizures, regression, and mortality.
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A rare neurodegenerative disorder of the astrocytes comprised of two clinical forms: Alexander disease (AxD) type I and type II manifesting with various degrees of macrocephaly, spasticity, ataxia and seizures and leading to psychomotor regression and death."
    explanation: Orphanet's definition supports the disease-level clinical framing used in this entry.
external_assertions:
- name: Orphanet Alexander disease record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:58
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=58
  description: >
    Orphanet curates ORPHA:58 as the Alexander disease disorder record and
    provides exact cross-references to MONDO:0008752, OMIM:203450, and
    ICD-11:8A44.2, with a narrower ICD-10:G93.8 cross-reference.
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ORPHA:58  Alexander disease"
    explanation: The Orphanet structured record heading identifies ORPHA:58 as the Alexander disease record.
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0008752 | Exact"
    explanation: Orphanet maps ORPHA:58 exactly to the MONDO disease identifier used by this entry.
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:203450 | Exact"
    explanation: Orphanet lists OMIM:203450 as an exact external cross-reference for Alexander disease.
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-10:G93.8 | Narrower"
    explanation: Orphanet lists ICD-10:G93.8 as a narrower cross-reference for Alexander disease.
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-11:8A44.2 | Exact"
    explanation: Orphanet lists ICD-11:8A44.2 as an exact cross-reference for Alexander disease.
parents:
- Leukodystrophies
- Neurodegenerative Disorders
has_subtypes:
- name: Type I
  display_name: Type I (Infantile)
  description: >
    Early-onset form characterized by seizures, macrocephaly, motor delay,
    encephalopathy, failure to thrive, and typical MRI features including
    frontal-predominant leukodystrophy. Associated with a nearly 2-fold
    increase in mortality relative to Type II.
  evidence:
  - reference: PMID:21917775
    reference_title: "GFAP mutations, age at onset, and clinical subtypes in Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Type I is characterized by early onset, seizures, macrocephaly, motor delay, encephalopathy, failure to thrive, paroxysmal deterioration, and typical MRI features"
    explanation: "Prust et al. defined Type I AxD based on latent class analysis of 215 patients."
- name: Type II
  display_name: Type II (Juvenile/Adult)
  description: >
    Later-onset form characterized by autonomic dysfunction, ocular movement
    abnormalities, bulbar symptoms, and atypical MRI features. Brainstem
    and spinal cord involvement predominate rather than frontal leukodystrophy.
  evidence:
  - reference: PMID:21917775
    reference_title: "GFAP mutations, age at onset, and clinical subtypes in Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Type II is characterized by later onset, autonomic dysfunction, ocular movement abnormalities, bulbar symptoms, and atypical MRI features"
    explanation: "Prust et al. defined Type II AxD based on latent class analysis."
inheritance:
- name: Autosomal Dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >
    Alexander disease is caused by heterozygous gain-of-function mutations
    in GFAP. The vast majority of cases are de novo. Missense mutations
    in the coding region of GFAP are found in most cases.
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal dominant"
    explanation: Orphanet records autosomal dominant inheritance for Alexander disease.
  - reference: PMID:11567214
    reference_title: "Infantile Alexander disease: spectrum of GFAP mutations and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Heterozygous, de novo mutations in the glial fibrillary acidic protein (GFAP) gene have recently been reported in 12 patients affected by neuropathologically proved Alexander disease"
    explanation: "Confirms de novo, heterozygous GFAP mutations as the genetic basis of infantile Alexander disease."
  - reference: PMID:11138011
    reference_title: "Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sequence analysis of DNA samples from patients representing different Alexander disease phenotypes revealed that most cases are associated with non-conservative mutations in the coding region of GFAP"
    explanation: "Original discovery paper identifying GFAP mutations as the cause of Alexander disease."
  - reference: PMID:20301351
    reference_title: "Alexander Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alexander disease is inherited in an autosomal dominant manner. To date, most reported individuals with molecularly confirmed Alexander disease have the disorder as the result of a de novo GFAP pathogenic variant; however, familial cases have been reported, including individuals with slowly progressive adult Alexander disease who have an affected parent."
    explanation: GeneReviews supports dominant inheritance while explicitly qualifying the predominance of de novo cases and the occurrence of familial adult disease.
prevalence:
- population: Japan (Orphanet annual incidence)
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BELOW_1_IN_1000000
  rate_high: 0.1
  percentage: "<1 / 1 000 000"
  notes: >
    Orphanet reports an annual-incidence class below 1 per 1,000,000 in Japan.
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "<1 / 1 000 000 | Japan | Annual incidence | PMID:21533827,EXPERT"
    explanation: The Orphanet epidemiology table reports the annual-incidence class for Alexander disease in Japan.
- population: Worldwide (Orphanet point prevalence)
  measure_type: POINT_PREVALENCE
  prevalence_class: UNKNOWN
  percentage: Unknown
  notes: Orphanet records the worldwide point-prevalence class as unknown.
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Unknown | Worldwide | Point prevalence | ORPHANET"
    explanation: The Orphanet epidemiology table records worldwide point prevalence as unknown.
progression:
- phase: Onset
  age_range: All ages
  notes: Orphanet classifies Alexander disease onset as possible at all ages.
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: All ages"
    explanation: Orphanet's natural-history section records all-age onset for Alexander disease.
pathophysiology:
- name: Mutant GFAP Proteotoxicity
  description: >
    Gain-of-function mutations in GFAP lead to accumulation of misfolded
    GFAP protein that forms Rosenthal fibers within astrocytes. These
    inclusions contain GFAP complexed with small heat shock proteins
    alphaB-crystallin and HSP27. The aggregation overwhelms the protein
    quality control machinery. Rosenthal fibers originate as small
    osmiophilic masses deposited on bundles of intermediate filaments and
    continue to form over time.
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  conforms_to: "loss_of_proteostasis#Misfolded-Protein Aggregation"
  genes:
  - preferred_term: GFAP
    term:
      id: hgnc:4235
      label: GFAP
  molecular_functions:
  - preferred_term: structural constituent of cytoskeleton
    term:
      id: GO:0005200
      label: structural constituent of cytoskeleton
  cell_types:
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Protein Aggregation
    term:
      id: GO:0070841
      label: inclusion body assembly
  evidence:
  - reference: PMID:11138011
    reference_title: "Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pathological hallmark of all forms of Alexander disease is the presence of Rosenthal fibers, cytoplasmic inclusions in astrocytes that contain the intermediate filament protein GFAP in association with small heat-shock proteins"
    explanation: "Defines Rosenthal fibers as the pathological hallmark, composed of GFAP with small heat-shock proteins."
  - reference: PMID:17498694
    reference_title: "GFAP and its role in Alexander disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the accumulation of GFAP and the formation of characteristic aggregates, called Rosenthal fibers, (ii) the sequestration of the protein chaperones alpha B-crystallin and HSP27 into Rosenthal fibers, and (iii) the activation of both Jnk and the stress response"
    explanation: "Reviews the multi-step pathogenic mechanism: GFAP accumulation, chaperone sequestration, and stress pathway activation."
  - reference: PMID:28359321
    reference_title: "The origin of Rosenthal fibers and their contributions to astrocyte pathology in Alexander disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "RFs appear to originate as small, osmiophilic masses containing both GFAP and alphaB-crystallin deposited on bundles of intermediate filaments"
    explanation: "Mouse model studies reveal the ultrastructural origin of Rosenthal fibers on intermediate filament bundles."
  downstream:
  - target: Astrocyte Dysfunction
    causal_link_type: DIRECT
    description: GFAP aggregation injures astrocytes, activating glial stress responses that secondarily impair neurons and oligodendrocytes.
    evidence:
    - reference: PMID:21414908
      reference_title: "Protein misfolding and oxidative stress promote glial-mediated neurodegeneration in an Alexander disease model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We also observe significant toxicity of mutant human GFAP to glia, which is mediated by protein aggregation and oxidative stress"
      explanation: "Mutant GFAP aggregation directly causes glial toxicity, supporting the edge from aggregate formation to astrocyte dysfunction."
  - target: White-Matter Oxidative Stress
    causal_link_type: DIRECT
    description: GFAP aggregation and Rosenthal fiber pathology are coupled to oxidative stress responses in white matter.
    evidence:
    - reference: PMID:17065456
      reference_title: "Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These studies provide formal proof linking GFAP mutations with Rosenthal fibers and oxidative stress"
      explanation: "Mouse knock-in data link GFAP mutation-driven Rosenthal fiber formation to oxidative stress."
- name: Astrocyte Dysfunction
  description: >
    Mutant GFAP-expressing astrocytes become dysfunctional, with activation
    of stress response pathways and white matter pathology. Elevated GFAP
    levels shift GFAP solubility and increase the stress response. Dysfunctional
    astrocytes fail to support neurons and oligodendrocytes, leading to
    secondary demyelination and neuronal loss.
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  conforms_to: "loss_of_proteostasis#Proteotoxic Cell Dysfunction and Neurodegeneration"
  cell_types:
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: Oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: Myelination
    term:
      id: GO:0042552
      label: myelination
  - preferred_term: Autophagy
    term:
      id: GO:0006914
      label: autophagy
  evidence:
  - reference: PMID:17065456
    reference_title: "Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "further elevation of GFAP via crosses to GFAP transgenic animals leads to a shift in GFAP solubility, an increased stress response, and ultimately death"
    explanation: "Mouse model demonstrates dose-dependent GFAP toxicity with solubility shift and lethal stress response."
  - reference: PMID:29226998
    reference_title: "Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "A key feature of pathogenesis is overexpression and accumulation of GFAP, with formation of characteristic cytoplasmic aggregates known as Rosenthal fibers"
    explanation: "Confirms GFAP overexpression and accumulation as central to pathogenesis."
  - reference: PMID:21414908
    reference_title: "Protein misfolding and oxidative stress promote glial-mediated neurodegeneration in an Alexander disease model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Both protein aggregation and oxidative stress contribute to activation of a robust autophagic response in glia"
    explanation: "Drosophila model shows that GFAP aggregation and oxidative stress activate autophagy in glial cells."
  downstream:
  - target: P2Y12-Dependent Protective Microglial Response
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced astrocytic NTPDase2 expression
    - increased extracellular ATP
    description: Dysfunctional Alexander disease astrocytes increase extracellular ATP signaling, which is sensed by microglial P2Y12 receptors and elicits a protective response in the mouse model.
    evidence:
    - reference: PMID:37955589
      reference_title: "Microglia sense astrocyte dysfunction and prevent disease progression in an Alexander disease model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Taken together, we demonstrated that microglia sense AxD astrocyte dysfunction via P2Y12 receptors as an increase in extracellular ATP and alter their morphology and Ca2+ signalling, thereby protecting against AxD pathology."
      explanation: The mouse study identifies the extracellular ATP–P2Y12 route by which microglia sense diseased astrocytes and limit pathology.
  - target: STAT3-Driven GFAP Upregulation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reactive astrocyte injury response
    description: Astrocyte injury and reactive signaling activate STAT3, which sustains pathological GFAP expression in a feed-forward loop demonstrated in mouse models.
    evidence:
    - reference: PMID:37048051
      reference_title: "STAT3 Drives GFAP Accumulation and Astrocyte Pathology in a Mouse Model of Alexander Disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "signal transducer and activator of transcription (STAT)-3 regulates Gfap during astrocyte development and in response to injury and is activated in astrocytes in rodent models of AxD."
      explanation: The model evidence supports injury-responsive STAT3 activation and GFAP regulation, while the exact direction of the feedback loop remains provisional in human disease.
  - target: Glutamate Excitotoxicity
    causal_link_type: DIRECT
    description: Toxic mutant GFAP in glia disrupts glial glutamate transport, creating a downstream excitotoxic route to neuronal injury.
    evidence:
    - reference: PMID:21414908
      reference_title: "Protein misfolding and oxidative stress promote glial-mediated neurodegeneration in an Alexander disease model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Toxicity of mutant GFAP to glial cells induces a non-cell-autonomous stress response and subsequent apoptosis in neurons, which is dependent on glial glutamate transport"
      explanation: "This links glial GFAP toxicity to glutamate-transport-dependent neuronal apoptosis."
  - target: Frontal-Predominant Leukoencephalopathy
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reactive astrogliosis
    - oligodendrocyte and myelin support failure
    description: Astrocyte dysfunction disrupts white matter support, contributing to the frontal-predominant leukoencephalopathy of Type I disease.
  - target: Macrocephaly
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - early-onset encephalopathy
    - white matter enlargement and dysfunction
    description: Severe early astrocyte and white matter pathology contributes to progressive head enlargement in Type I disease.
  - target: Spasticity
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticospinal tract dysfunction
    - brainstem and spinal cord involvement
    description: Astrocyte-driven white matter and corticospinal pathway dysfunction contributes to progressive spasticity.
  - target: Dysphagia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - bulbar pathway dysfunction
    - brainstem involvement
    description: Brainstem and bulbar network involvement from astrocyte pathology contributes to dysphagia.
  - target: Dysarthria
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - bulbar pathway dysfunction
    - brainstem involvement
    description: Brainstem and bulbar motor pathway involvement from astrocyte pathology contributes to dysarthria.
  - target: Ataxia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cerebellar circuit dysfunction
    - brainstem involvement
    description: Astrocyte pathology in posterior fossa circuits contributes to ataxia in juvenile and adult-onset disease.
  - target: Autonomic Dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - brainstem autonomic network involvement
    description: Type II brainstem involvement provides the mechanistic route from astrocyte pathology to autonomic dysfunction.
  - target: Nystagmus
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - ocular motor pathway dysfunction
    - brainstem and cerebellar involvement
    description: Astrocyte pathology affecting brainstem and cerebellar ocular motor circuits contributes to nystagmus.
  - target: Failure to Thrive
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - encephalopathy
    - feeding dysfunction
    description: Severe early astrocyte and white matter pathology contributes to encephalopathy and feeding difficulty, producing failure to thrive in Type I disease.
  - target: Intellectual Disability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - early-onset encephalopathy
    - progressive white matter dysfunction
    description: Early astrocyte and white matter pathology impairs neurodevelopmental function in Type I disease.
  - target: Global Developmental Delay
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - early-onset encephalopathy
    - progressive white matter dysfunction
    description: Early cerebral astrocyte and white matter pathology delays acquisition of developmental milestones in Type I disease.
  - target: Hyperreflexia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticospinal tract dysfunction
    - upper motor neuron pathway involvement
    description: Astrocyte-driven corticospinal pathway dysfunction produces pyramidal signs such as hyperreflexia.
  - target: Clonus
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticospinal tract dysfunction
    - upper motor neuron pathway involvement
    description: Corticospinal pathway involvement produces clonus as part of the pyramidal-sign phenotype.
  - target: Abnormal Pyramidal Sign
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticospinal tract dysfunction
    - upper motor neuron pathway involvement
    description: Astrocyte and white matter pathology affecting corticospinal tracts produces abnormal pyramidal signs.
  - target: Megalencephaly
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - early-onset encephalopathy
    - white matter enlargement and dysfunction
    description: Type I astrocyte and white matter pathology contributes to brain enlargement captured as megalencephaly.
  - target: Frontal Bossing
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - macrocephaly
    - early craniofacial remodeling
    description: Cranial enlargement in Type I disease contributes to frontal bossing.
  - target: Large Face
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - macrocephaly
    - craniofacial overgrowth pattern
    description: The Type I cranial enlargement phenotype is associated with a large-face craniofacial appearance.
  - target: Abnormality of Speech or Vocalization
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - bulbar pathway dysfunction
    - cerebellar and brainstem involvement
    description: Astrocyte pathology affecting bulbar, cerebellar, and brainstem circuits contributes to abnormal speech or vocalization.
  - target: Nausea and Vomiting
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - brainstem involvement
    - autonomic pathway dysfunction
    description: Brainstem and autonomic involvement provides the route to nausea and vomiting in later-onset disease.
  - target: Sleep Abnormality
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - brainstem network involvement
    description: Diffuse astrocyte-driven neurologic dysfunction likely contributes to sleep disturbance, although the specific sleep-circuit intermediates are not yet resolved.
  - target: Scoliosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - chronic axial motor dysfunction
    - corticospinal and brainstem involvement
    description: Chronic motor pathway involvement in later-onset disease contributes to scoliosis.
- name: White-Matter Oxidative Stress
  description: >
    GFAP mutations induce an antioxidant/oxidative stress response in
    white matter, with iron accumulation in corpus callosum. Knock-in mice
    with GFAP mutations show a distinct pattern of stress response gene
    induction particularly prominent in white matter regions.
  biological_scale: TISSUE
  mechanism_confidence: ESTABLISHED
  cell_types:
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Oxidative Stress Response
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:17065456
    reference_title: "Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "when crossed with an antioxidant response element reporter line, the mutant mice show a distinct pattern of reporter-gene induction that is especially prominent in the corpus callosum, and histochemical staining reveals accumulation of iron in the same region"
    explanation: "GFAP mutant mice show oxidative stress response and iron accumulation in white matter."
  downstream:
  - target: Oxidative GFAP Crosslinking
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - astrocyte oxidant exposure
    - oxidative modification of GFAP cysteine residues
    description: Oxidant stress modifies GFAP and promotes disulfide-linked oligomerization, closing a model-supported cycle between mutant GFAP proteotoxicity and oxidative injury.
    evidence:
    - reference: PMID:41830670
      reference_title: "Alexander disease mutations differentially sensitize glial fibrillary acidic protein (GFAP) to posttranslational modifications and network disruption by oxidants."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Cellular expression of certain GFAP AxD mutants can provoke oxidative stress and contribute to a pathogenic cycle, as GFAP itself is an important oxidant target."
      explanation: Cell and in-vitro data support a reciprocal route from oxidant stress to modification of mutant GFAP; the white-matter tissue context remains model-derived.
  - target: Frontal-Predominant Leukoencephalopathy
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corpus callosum and frontal white matter stress response
    - myelin support failure
    description: Oxidative stress in white matter regions contributes to the leukodystrophy phenotype.
  - target: Seizures
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - astrocyte stress response
    - altered neuronal excitability
    description: GFAP mutant white matter stress and gliosis increase seizure susceptibility.
    evidence:
    - reference: PMID:17065456
      reference_title: "Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "The mutant mice have a normal lifespan and show no overt behavioral defects, but are more susceptible to kainate-induced seizures"
      explanation: "GFAP mutant mice show increased seizure susceptibility downstream of astrocyte and white matter stress."
- name: Glutamate Excitotoxicity
  description: >
    Dysfunctional astrocytes in Alexander disease show impaired glutamate
    uptake via astrocytic transporters, leading to toxic accumulation of
    extracellular glutamate. This non-cell-autonomous mechanism causes
    neuronal apoptosis dependent on glial glutamate transport.
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  cell_types:
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Neurotransmitter Transport
    term:
      id: GO:0006836
      label: neurotransmitter transport
  evidence:
  - reference: PMID:21414908
    reference_title: "Protein misfolding and oxidative stress promote glial-mediated neurodegeneration in an Alexander disease model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Toxicity of mutant GFAP to glial cells induces a non-cell-autonomous stress response and subsequent apoptosis in neurons, which is dependent on glial glutamate transport"
    explanation: "Drosophila model demonstrates that mutant GFAP toxicity to glia causes neuronal apoptosis via glutamate-dependent mechanism."
  downstream:
  - target: Seizures
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired glial glutamate transport
    - neuronal hyperexcitability
    description: Impaired glial glutamate handling provides a plausible excitotoxic route to seizures.
  - target: Psychomotor Regression
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - neuronal apoptosis
    - progressive network failure
    description: Non-cell-autonomous neuronal apoptosis contributes to progressive developmental regression and neurologic decline.
  - target: EEG Abnormality
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - neuronal hyperexcitability
    - seizure-prone cortical networks
    description: Glutamate-mediated hyperexcitability and seizures provide a route to abnormal EEG findings.
- name: Oxidative GFAP Crosslinking
  description: >
    Disease-associated GFAP mutations promote pathological post-translational
    modifications including aberrant disulfide cross-linking (particularly
    cysteine-generating mutations like R239C) and ubiquitination. These
    modifications yield high-molecular-weight insoluble GFAP species that
    contribute to Rosenthal fiber formation and resist proteolytic clearance.
  biological_scale: MOLECULAR
  mechanism_confidence: PROVISIONAL
  genes:
  - preferred_term: GFAP
    term:
      id: hgnc:4235
      label: GFAP
  molecular_functions:
  - preferred_term: structural constituent of cytoskeleton
    term:
      id: GO:0005200
      label: structural constituent of cytoskeleton
  cell_types:
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Protein Ubiquitination
    term:
      id: GO:0016567
      label: protein ubiquitination
  evidence:
  - reference: PMID:38782207
    reference_title: "Glial fibrillary acidic protein is pathologically modified in Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found high molecular weight GFAP species in the RFs of AxD brains, indicating abnormal GFAP crosslinking as a prominent pathological feature of this disease"
    explanation: "Analysis of AxD patient brain tissue identifies aberrant GFAP crosslinking as a key pathological modification."
  - reference: PMID:38782207
    reference_title: "Glial fibrillary acidic protein is pathologically modified in Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we found GFAP was ubiquitinated in RFs of AxD patients"
    explanation: "Patient brain Rosenthal fibers show GFAP ubiquitination, supporting this modification as part of human aggregation pathology."
  - reference: PMID:41830670
    reference_title: "Alexander disease mutations differentially sensitize glial fibrillary acidic protein (GFAP) to posttranslational modifications and network disruption by oxidants."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Formation of disulfide bonds, some of which involved mutation-introduced cysteine residues, results in GFAP oligomerization in vitro and in cells."
    explanation: Cell and in-vitro experiments directly show disulfide-linked GFAP oligomerization, including crosslinks involving mutation-introduced cysteines.
  downstream:
  - target: Mutant GFAP Proteotoxicity
    causal_link_type: DIRECT
    description: Oxidation, crosslinking, and ubiquitination decrease GFAP solubility and promote Rosenthal fiber aggregation.
    evidence:
    - reference: PMID:38782207
      reference_title: "Glial fibrillary acidic protein is pathologically modified in Alexander disease."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "cystine-generating mutations promote GFAP crosslinking by cysteine-dependent oxidation, resulting in defective GFAP assembly and decreased filament solubility"
      explanation: "Cell-based and in vitro evidence supports a direct path from cysteine-generating GFAP variants through crosslinking to insoluble aggregate formation."
- name: STAT3-Driven GFAP Upregulation
  description: >
    Activated STAT3 sustains pathological GFAP expression in Alexander disease
    astrocytes. Astrocyte-specific Stat3 deletion after pathology was established
    reversed GFAP accumulation and aggregation in mice, identifying a modifiable
    feed-forward driver rather than merely a marker of reactive gliosis.
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  genes:
  - preferred_term: STAT3
    term:
      id: hgnc:11364
      label: STAT3
  cell_types:
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  evidence:
  - reference: PMID:37048051
    reference_title: "STAT3 Drives GFAP Accumulation and Astrocyte Pathology in a Mouse Model of Alexander Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this report, we show that STAT3 is also activated in the human disease."
    explanation: Patient tissue establishes that STAT3 activation is present in human Alexander disease, while not by itself establishing causal direction.
  - reference: PMID:37048051
    reference_title: "STAT3 Drives GFAP Accumulation and Astrocyte Pathology in a Mouse Model of Alexander Disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Astrocyte-specific Stat3 knockout in adult mice with existing pathology reversed GFAP accumulation and aggregation."
    explanation: Conditional knockout after disease pathology had developed provides intervention evidence that STAT3 drives GFAP accumulation in the mouse model.
  downstream:
  - target: Mutant GFAP Proteotoxicity
    causal_link_type: DIRECT
    description: STAT3-dependent elevation of GFAP increases the protein burden that accumulates and aggregates in Alexander disease astrocytes.
    evidence:
    - reference: PMID:37048051
      reference_title: "STAT3 Drives GFAP Accumulation and Astrocyte Pathology in a Mouse Model of Alexander Disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Astrocyte-specific Stat3 knockout in adult mice with existing pathology reversed GFAP accumulation and aggregation."
      explanation: Reversal of GFAP accumulation after Stat3 deletion supports a direct regulatory link in the disease model.
- name: P2Y12-Dependent Protective Microglial Response
  description: >
    Microglia detect excess extracellular ATP arising from dysfunctional
    Alexander disease astrocytes through P2Y12 receptors. Pharmacologic P2Y12
    blockade worsened pathological markers in mice, supporting a compensatory,
    protective microglial response rather than a disease-driving inflammatory step.
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  cell_types:
  - preferred_term: Microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  evidence:
  - reference: PMID:37955589
    reference_title: "Microglia sense astrocyte dysfunction and prevent disease progression in an Alexander disease model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Clopidogrel significantly exacerbated pathological markers in AxD model mice and attenuated the morphological features of microglia, suggesting that microglia play a protective role against AxD pathology via P2Y12 receptors."
    explanation: P2Y12 inhibition worsened disease-model pathology, supporting a protective role for P2Y12-dependent microglial activity.
phenotypes:
- category: Clinical
  name: Global Developmental Delay
  frequency: VERY_FREQUENT
  description: >
    Developmental delay is usually the earliest recognized feature of cerebral
    Alexander disease; in a 51-person cohort it preceded the mean onset of
    seizures and macrocephaly.
  subtype: Type I
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:37920915
    reference_title: "Acquisition and Loss of Developmental Milestones and Time to Disease-Related Outcomes in Cerebral Alexander Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Developmental delay was the earliest and most prevalent symptom"
    explanation: The 51-person cerebral-phenotype cohort identifies developmental delay as the earliest and most prevalent of the classic pediatric features.
- category: Clinical
  name: Macrocephaly
  frequency: VERY_FREQUENT
  description: >
    Progressive enlargement of the head, particularly prominent in Type I
    (infantile) Alexander disease. Often the presenting feature.
  subtype: Type I
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000256 | Macrocephaly | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies macrocephaly as very frequent in Alexander disease.
  - reference: PMID:11138011
    reference_title: "Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures and psychomotor retardation"
    explanation: "Macrocephaly is a cardinal feature of infantile Alexander disease."
  - reference: PMID:21917775
    reference_title: "GFAP mutations, age at onset, and clinical subtypes in Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Type I is characterized by early onset, seizures, macrocephaly, motor delay, encephalopathy, failure to thrive, paroxysmal deterioration, and typical MRI features"
    explanation: "Macrocephaly is a defining feature of Type I Alexander disease."
  - reference: PMID:37920915
    reference_title: "Acquisition and Loss of Developmental Milestones and Time to Disease-Related Outcomes in Cerebral Alexander Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical triad of developmental delay, seizures, and macrocephaly are not universally present in cerebral Alexander disease."
    explanation: A 51-patient cerebral-phenotype cohort documented macrocephaly in 28 participants (55%), within the FREQUENT rather than VERY_FREQUENT band; the association is retained but its frequency is cohort-dependent.
- category: Clinical
  name: Frontal-Predominant Leukoencephalopathy
  description: >
    Frontal-predominant white matter abnormality on MRI, a hallmark
    diagnostic imaging feature of Type I Alexander disease.
  subtype: Type I
  diagnostic: true
  phenotype_term:
    preferred_term: Frontal-predominant leukoencephalopathy
    term:
      id: HP:0002352
      label: Leukoencephalopathy
  evidence:
  - reference: PMID:11138011
    reference_title: "Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures and psychomotor retardation"
    explanation: "Leukoencephalopathy is a defining feature of infantile Alexander disease."
  - reference: PMID:21917775
    reference_title: "GFAP mutations, age at onset, and clinical subtypes in Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Type I is characterized by early onset, seizures, macrocephaly, motor delay, encephalopathy, failure to thrive, paroxysmal deterioration, and typical MRI features"
    explanation: "Typical MRI features including frontal-predominant leukodystrophy define Type I."
- category: Clinical
  name: Seizures
  frequency: VERY_FREQUENT
  description: >
    Seizures are common in Type I Alexander disease, often presenting in
    the first year of life. GFAP mutant mice also show increased
    susceptibility to kainate-induced seizures.
  subtype: Type I
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies seizures as very frequent in Alexander disease.
  - reference: PMID:11138011
    reference_title: "Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures and psychomotor retardation"
    explanation: "Seizures are a primary clinical feature of infantile Alexander disease."
  - reference: PMID:17065456
    reference_title: "Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The mutant mice have a normal lifespan and show no overt behavioral defects, but are more susceptible to kainate-induced seizures"
    explanation: "GFAP mutant knock-in mice recapitulate seizure susceptibility."
  - reference: PMID:41581419
    reference_title: "Natural History and Prognostic Factors in Pediatric Alexander Disease: A Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The overall prognosis of Alexander disease is poor, with an average age at death of 18.6 ± 1.4 years and a high incidence of epilepsy (81.5%)."
    explanation: The pediatric multicenter cohort independently supports very frequent epilepsy in early-onset disease; its mortality estimate is specific to that cohort.
- category: Clinical
  name: Spasticity
  frequency: VERY_FREQUENT
  description: >
    Progressive spasticity affecting the limbs, present in both Type I
    and Type II Alexander disease. In juvenile and adult forms, spasticity
    is a prominent feature alongside bulbar signs.
  subtypes:
  - Type I
  - Type II
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001257 | Spasticity | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies spasticity as very frequent in Alexander disease.
  - reference: PMID:11138011
    reference_title: "Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course"
    explanation: "Spasticity is a characteristic feature of juvenile/adult Alexander disease."
- category: Clinical
  name: Dysphagia
  frequency: FREQUENT
  description: >
    Difficulty swallowing, particularly prominent in Type II Alexander
    disease as part of the bulbar symptom complex.
  subtype: Type II
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002015 | Dysphagia | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies dysphagia as frequent in Alexander disease.
  - reference: PMID:21917775
    reference_title: "GFAP mutations, age at onset, and clinical subtypes in Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Type II is characterized by later onset, autonomic dysfunction, ocular movement abnormalities, bulbar symptoms, and atypical MRI features"
    explanation: "Dysphagia is part of the bulbar symptom complex defining Type II AxD."
- category: Clinical
  name: Dysarthria
  frequency: FREQUENT
  description: >
    Impaired speech articulation due to bulbar involvement, common
    in juvenile and adult-onset forms.
  subtype: Type II
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001260 | Dysarthria | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies dysarthria as frequent in Alexander disease.
  - reference: PMID:11138011
    reference_title: "Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course"
    explanation: "Dysarthria is part of the bulbar signs characterizing juvenile/adult Alexander disease."
- category: Clinical
  name: Ataxia
  frequency: FREQUENT
  description: >
    Cerebellar ataxia present in juvenile and adult forms of Alexander disease.
  subtype: Type II
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001251 | Ataxia | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies ataxia as frequent in Alexander disease.
  - reference: PMID:11138011
    reference_title: "Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity"
    explanation: "Ataxia is characteristic of juvenile/adult Alexander disease."
- category: Clinical
  name: Psychomotor Regression
  frequency: OCCASIONAL
  description: >
    Loss of previously acquired developmental milestones, characteristic
    of infantile Alexander disease, leading to death usually within the
    first decade.
  subtype: Type I
  phenotype_term:
    preferred_term: Psychomotor deterioration
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002376 | Developmental regression | Occasional (29-5%)"
    explanation: Orphanet's curated HPO table classifies developmental regression as occasional in Alexander disease.
  - reference: PMID:11138011
    reference_title: "Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures and psychomotor retardation, leading to death usually within the first decade"
    explanation: "Psychomotor retardation with progressive decline is a hallmark of infantile Alexander disease."
- category: Clinical
  name: Autonomic Dysfunction
  frequency: OCCASIONAL
  description: >
    Autonomic nervous system dysfunction including abnormal sweating,
    cardiovascular instability, and gastrointestinal dysmotility. A
    defining feature of Type II Alexander disease, reflecting brainstem
    involvement.
  subtype: Type II
  phenotype_term:
    preferred_term: Autonomic dysfunction
    term:
      id: HP:0012332
      label: Abnormal autonomic nervous system physiology
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012332 | Abnormal autonomic nervous system physiology | Occasional (29-5%)"
    explanation: Orphanet's curated HPO table classifies abnormal autonomic nervous system physiology as occasional in Alexander disease.
  - reference: PMID:21917775
    reference_title: "GFAP mutations, age at onset, and clinical subtypes in Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Type II is characterized by later onset, autonomic dysfunction, ocular movement abnormalities, bulbar symptoms, and atypical MRI features"
    explanation: "Autonomic dysfunction is a defining feature of Type II Alexander disease."
- category: Clinical
  name: Failure to Thrive
  frequency: VERY_FREQUENT
  description: >
    Poor weight gain and growth failure, particularly in infantile
    Alexander disease. Often accompanies feeding difficulties and
    progressive encephalopathy.
  subtype: Type I
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001508 | Failure to thrive | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies failure to thrive as very frequent in Alexander disease.
  - reference: PMID:21917775
    reference_title: "GFAP mutations, age at onset, and clinical subtypes in Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Type I is characterized by early onset, seizures, macrocephaly, motor delay, encephalopathy, failure to thrive, paroxysmal deterioration, and typical MRI features"
    explanation: "Failure to thrive is a defining feature of Type I Alexander disease."
- category: Clinical
  name: Nystagmus
  frequency: FREQUENT
  description: >
    Involuntary rhythmic eye movements reflecting cerebellar or
    brainstem involvement, observed particularly in adult-onset
    Alexander disease as part of ocular movement abnormalities.
  subtype: Type II
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000639 | Nystagmus | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies nystagmus as frequent in Alexander disease.
  - reference: PMID:21917775
    reference_title: "GFAP mutations, age at onset, and clinical subtypes in Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Type II is characterized by later onset, autonomic dysfunction, ocular movement abnormalities, bulbar symptoms, and atypical MRI features"
    explanation: "Ocular movement abnormalities including nystagmus are characteristic of Type II Alexander disease."
- category: Clinical
  name: Intellectual Disability
  frequency: VERY_FREQUENT
  description: >
    Intellectual disability is a prominent Type I Alexander disease feature,
    reflecting early and progressive neurodevelopmental involvement.
  subtype: Type I
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001249 | Intellectual disability | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies intellectual disability as very frequent in Alexander disease.
- category: Clinical
  name: Hyperreflexia
  frequency: VERY_FREQUENT
  description: >
    Hyperreflexia is a pyramidal tract sign in Alexander disease, consistent
    with corticospinal pathway involvement.
  phenotype_term:
    preferred_term: Hyperreflexia
    term:
      id: HP:0001347
      label: Hyperreflexia
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001347 | Hyperreflexia | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies hyperreflexia as very frequent in Alexander disease.
- category: Clinical
  name: Megalencephaly
  frequency: VERY_FREQUENT
  description: >
    Megalencephaly captures brain enlargement in Type I Alexander disease,
    complementing the macrocephaly phenotype.
  subtype: Type I
  phenotype_term:
    preferred_term: Megalencephaly
    term:
      id: HP:0001355
      label: Megalencephaly
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001355 | Megalencephaly | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies megalencephaly as very frequent in Alexander disease.
- category: Clinical
  name: Frontal Bossing
  frequency: VERY_FREQUENT
  description: >
    Frontal bossing is a craniofacial manifestation in the Type I Alexander
    disease phenotype, often occurring with macrocephaly.
  subtype: Type I
  phenotype_term:
    preferred_term: Frontal bossing
    term:
      id: HP:0002007
      label: Frontal bossing
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002007 | Frontal bossing | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies frontal bossing as very frequent in Alexander disease.
- category: Clinical
  name: Nausea and Vomiting
  frequency: VERY_FREQUENT
  description: >
    Nausea and vomiting are included in Orphanet's very frequent phenotype
    annotations and may reflect brainstem involvement in later-onset disease.
  subtype: Type II
  phenotype_term:
    preferred_term: Nausea and vomiting
    term:
      id: HP:0002017
      label: Nausea and vomiting
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002017 | Nausea and vomiting | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies nausea and vomiting as very frequent in Alexander disease.
- category: Clinical
  name: Abnormality of Speech or Vocalization
  frequency: VERY_FREQUENT
  description: >
    Speech or vocalization abnormalities are consistent with bulbar,
    cerebellar, and progressive neurologic involvement in Alexander disease.
  phenotype_term:
    preferred_term: Abnormality of speech or vocalization
    term:
      id: HP:0002167
      label: Abnormal speech pattern
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002167 | Abnormality of speech or vocalization | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies abnormality of speech or vocalization as very frequent in Alexander disease.
- category: Clinical
  name: Clonus
  frequency: VERY_FREQUENT
  description: >
    Clonus is a corticospinal tract sign that fits the pyramidal involvement
    seen across Alexander disease.
  phenotype_term:
    preferred_term: Clonus
    term:
      id: HP:0002169
      label: Clonus
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002169 | Clonus | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies clonus as very frequent in Alexander disease.
- category: Clinical
  name: EEG Abnormality
  frequency: VERY_FREQUENT
  description: >
    EEG abnormality accompanies the seizure-prone Type I Alexander disease
    phenotype.
  subtype: Type I
  phenotype_term:
    preferred_term: EEG abnormality
    term:
      id: HP:0002353
      label: EEG abnormality
  electrophysiology:
    electrophysiology_modality: EEG
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002353 | EEG abnormality | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies EEG abnormality as very frequent in Alexander disease.
- category: Clinical
  name: Sleep Abnormality
  frequency: VERY_FREQUENT
  description: >
    Sleep abnormality is included in Orphanet's very frequent phenotype
    annotations for Alexander disease.
  phenotype_term:
    preferred_term: Sleep abnormality
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002360 | Sleep abnormality | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies sleep abnormality as very frequent in Alexander disease.
- category: Clinical
  name: Scoliosis
  frequency: VERY_FREQUENT
  description: >
    Scoliosis is listed by Orphanet as a very frequent skeletal manifestation
    and is especially relevant to later-onset Alexander disease.
  subtype: Type II
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002650 | Scoliosis | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies scoliosis as very frequent in Alexander disease.
- category: Clinical
  name: Abnormal Pyramidal Sign
  frequency: VERY_FREQUENT
  description: >
    Abnormal pyramidal signs reflect corticospinal tract involvement in
    Alexander disease.
  phenotype_term:
    preferred_term: Abnormal pyramidal sign
    term:
      id: HP:0007256
      label: Abnormal pyramidal sign
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007256 | Abnormal pyramidal sign | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies abnormal pyramidal sign as very frequent in Alexander disease.
- category: Clinical
  name: Large Face
  frequency: VERY_FREQUENT
  description: >
    Large face is a craniofacial feature included in Orphanet's very frequent
    annotations for the Type I Alexander disease phenotype.
  subtype: Type I
  phenotype_term:
    preferred_term: Large face
    term:
      id: HP:0100729
      label: Large face
  evidence:
  - reference: ORPHA:58
    reference_title: "Alexander disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0100729 | Large face | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies large face as very frequent in Alexander disease.
imaging_findings:
- name: Frontal-predominant cerebral white-matter abnormalities on MRI
  modality: MRI
  imaging_finding_term:
    preferred_term: Leukoencephalopathy
    term:
      id: HP:0002352
      label: Leukoencephalopathy
  phenotype_term:
    preferred_term: Leukoencephalopathy
    term:
      id: HP:0002352
      label: Leukoencephalopathy
  located_in:
    preferred_term: brain white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  diagnostic: true
  subtype: Type I
  context: Characteristic cerebral pattern in infantile and juvenile disease; molecular confirmation remains definitive.
  description: Brain MRI commonly shows frontal-predominant cerebral white-matter abnormalities in early-onset Alexander disease.
  evidence:
  - reference: PMID:21533827
    reference_title: "Nationwide survey of Alexander disease in Japan and proposed new guidelines for diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The main characteristics of infantile and juvenile AxD include delayed psychomotor development or mental retardation, convulsions, macrocephaly, and predominant cerebral white matter abnormalities in the frontal lobe on brain MRI."
    explanation: The nationwide survey directly supports the frontal-predominant cerebral MRI pattern in early-onset disease.
- name: Medulla-oblongata signal abnormality or atrophy on MRI
  modality: MRI
  diagnostic: true
  subtype: Type II
  located_in:
    preferred_term: medulla oblongata
    term:
      id: UBERON:0001896
      label: medulla oblongata
  context: One component of the characteristic adult bulbospinal pattern; molecular confirmation remains definitive.
  description: Adult Alexander disease commonly shows medulla-oblongata signal abnormality or atrophy on MRI.
  evidence:
  - reference: PMID:21533827
    reference_title: "Nationwide survey of Alexander disease in Japan and proposed new guidelines for diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The main characteristics of adult AxD include bulbar signs, muscle weakness with hyperreflexia, and signal abnormalities and/or atrophy of medulla oblongata and cervical spinal cord on MRI."
    explanation: The nationwide survey directly supports medulla-oblongata signal abnormality or atrophy as part of the adult bulbospinal MRI pattern.
- name: Cervical spinal-cord signal abnormality or atrophy on MRI
  modality: MRI
  diagnostic: true
  subtype: Type II
  located_in:
    preferred_term: cervical spinal cord
    term:
      id: UBERON:0002726
      label: cervical spinal cord
  context: One component of the characteristic adult bulbospinal pattern; molecular confirmation remains definitive.
  description: Adult Alexander disease commonly shows cervical spinal-cord signal abnormality or atrophy on MRI.
  evidence:
  - reference: PMID:21533827
    reference_title: "Nationwide survey of Alexander disease in Japan and proposed new guidelines for diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The main characteristics of adult AxD include bulbar signs, muscle weakness with hyperreflexia, and signal abnormalities and/or atrophy of medulla oblongata and cervical spinal cord on MRI."
    explanation: The nationwide survey directly supports cervical spinal-cord signal abnormality or atrophy as part of the adult bulbospinal MRI pattern.
histopathology:
- name: Astrocytic Rosenthal fibers
  description: >
    Cytoplasmic astrocyte inclusions containing GFAP and small heat-shock proteins
    are the pathological hallmark of all forms, but their presence should be
    interpreted with clinical, imaging, and molecular findings.
  diagnostic: false
  context: Hallmark neuropathologic finding that is not independently pathognomonic because Rosenthal fibers can occur in other neoplastic and chronic reactive conditions.
  evidence:
  - reference: PMID:11138011
    reference_title: "Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pathological hallmark of all forms of Alexander disease is the presence of Rosenthal fibers, cytoplasmic inclusions in astrocytes that contain the intermediate filament protein GFAP in association with small heat-shock proteins"
    explanation: Human neuropathology establishes the characteristic inclusion, its astrocytic location, and its composition.
biochemical:
- name: Cerebrospinal-fluid and plasma GFAP
  presence: INCREASED
  context: Elevated across the clinical spectrum; concentrations are higher in the cerebral phenotype and rise over time in young children.
  readouts:
  - target: Mutant GFAP Proteotoxicity
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated soluble GFAP in CSF or plasma reports the abnormal GFAP burden but is not independently diagnostic of Alexander disease.
    evidence:
    - reference: PMID:41513585
      reference_title: "Characterization of Clinical Phenotype to Glial Fibrillary Acidic Protein Concentrations in Alexander Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "GFAP concentrations were significantly elevated at baseline in both AxD CSF (N = 44) compared to controls (N = 46, p < 0.0001) and AxD plasma (N = 96) compared to other leukodystrophy plasma controls (N = 67, p < 0.0001)."
      explanation: The human cohort directly links elevated CSF and plasma GFAP to Alexander disease relative to control groups.
  evidence:
  - reference: PMID:41513585
    reference_title: "Characterization of Clinical Phenotype to Glial Fibrillary Acidic Protein Concentrations in Alexander Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GFAP concentrations are higher in the cerebral phenotype and increase over time in young children."
    explanation: This supports phenotype and age dependence, preventing overgeneralization of a single reference range across the disease spectrum.
  - reference: PMID:38558318
    reference_title: "Plasma concentrations of glial fibrillary acidic protein, neurofilament light, and tau in Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we report that GFAP is elevated in plasma of all age groups afflicted by AxD, including those with adult onset."
    explanation: The plasma study supports biomarker elevation across age groups, including adult-onset disease.
diagnosis:
- name: Clinical and MRI assessment with molecular confirmation
  description: >
    Suggestive age-dependent clinical and neuroimaging findings prompt testing;
    identification of a heterozygous pathogenic GFAP variant establishes the
    diagnosis.
  evidence:
  - reference: PMID:20301351
    reference_title: "Alexander Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of Alexander disease is established in a proband with suggestive clinical and neuroimaging findings and a heterozygous pathogenic variant in GFAP identified by molecular genetic testing."
    explanation: GeneReviews defines the integrated clinical, imaging, and molecular route to diagnosis and the definitive molecular finding.
  - reference: PMID:21533827
    reference_title: "Nationwide survey of Alexander disease in Japan and proposed new guidelines for diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To ensure correct diagnosis of AxD, the physician should understand the importance of the process of GFAP genetic testing, which provides definitive diagnosis."
    explanation: The nationwide diagnostic guideline independently identifies GFAP testing as definitive.
genetic:
- name: GFAP Gain-of-Function Mutations
  gene_term:
    preferred_term: GFAP
    term:
      id: hgnc:4235
      label: GFAP
  association: Causative
  notes: >
    Heterozygous missense mutations in GFAP account for the vast majority of cases.
    Hotspot mutations at R79 and R239 are most common, accounting for 16.6% and
    20.3% of the 2011 cohort respectively. R239 variants as a group are associated
    with early, severe disease, but age at onset differs among substitutions at
    that residue. Most cases are de novo, although familial disease occurs. The
    mutations cause a toxic gain of function leading to protein aggregation rather
    than haploinsufficiency.
  inheritance:
  - name: Autosomal Dominant
  variants:
  - name: GFAP R79 missense hotspot
    description: >
      Recurrent heterozygous GFAP R79 substitutions, especially R79H, are a
      common Alexander disease hotspot. They enter the canonical toxic
      gain-of-function path from mutant GFAP through Rosenthal fiber formation,
      astrocyte dysfunction, white matter injury, and subtype-specific neurologic
      phenotypes.
    gene:
      preferred_term: GFAP
      term:
        id: hgnc:4235
        label: GFAP
    type: missense
    clinical_significance: PATHOGENIC
    functional_effects:
    - function: toxic gain-of-function
      description: Missense substitution in the GFAP rod domain promotes dominant astrocyte intermediate-filament pathology.
    evidence:
    - reference: PMID:11567214
      reference_title: "Infantile Alexander disease: spectrum of GFAP mutations and genotype-phenotype correlation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Nine patients carried arginine mutations (four had R79H; four had R239C; and one had R239H)"
      explanation: "Documents R79H among recurrent arginine hotspot mutations in infantile Alexander disease."
    - reference: PMID:21917775
      reference_title: "GFAP mutations, age at onset, and clinical subtypes in Alexander disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "R79 and R239 GFAP mutations were most common (16.6% and 20.3% of all cases, respectively)"
      explanation: "Large cohort analysis identifies R79 as one of the two most common GFAP mutation sites."
  - name: GFAP R239 missense hotspot
    description: >
      Recurrent heterozygous GFAP R239 substitutions, including R239C and R239H,
      are the most common hotspot group and are associated with a more aggressive
      clinical course, while R239H has earlier onset than R239C. R239 variants
      follow the toxic GFAP path through aggregation,
      Rosenthal fibers, astrocyte dysfunction, and severe Type I-weighted
      neurologic phenotypes.
    gene:
      preferred_term: GFAP
      term:
        id: hgnc:4235
        label: GFAP
    type: missense
    clinical_significance: PATHOGENIC
    functional_effects:
    - function: toxic gain-of-function
      description: Missense substitution at GFAP Arg239 promotes dominant GFAP aggregation and severe astrocyte pathology.
    evidence:
    - reference: PMID:11567214
      reference_title: "Infantile Alexander disease: spectrum of GFAP mutations and genotype-phenotype correlation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Nine patients carried arginine mutations (four had R79H; four had R239C; and one had R239H)"
      explanation: "Identifies R239C and R239H among recurrent GFAP hotspot mutations."
    - reference: PMID:21917775
      reference_title: "GFAP mutations, age at onset, and clinical subtypes in Alexander disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These common mutations predicted distinct clinical outcomes, with R239 predicting the most aggressive course"
      explanation: "Links the R239 hotspot to the most aggressive clinical trajectory."
    - reference: PMID:40520824
      reference_title: "Genotype-Phenotype Association for 14 GFAP Variants in Alexander Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Pairwise comparison results found that R239H was associated with significantly earlier onsets than R239C."
      explanation: A newer variant-level analysis qualifies the hotspot association by demonstrating heterogeneity among R239 substitutions.
    - reference: PMID:41581419
      reference_title: "Natural History and Prognostic Factors in Pediatric Alexander Disease: A Cohort Study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "patients with variants of R239 had a greater incidence of poor outcome than other variants did"
      explanation: The pediatric cohort supports poorer outcome for R239 variants while keeping the inference scoped to pediatric patients.
  - name: GFAP cysteine-generating aggregation-prone variants
    description: >
      Cysteine-generating GFAP variants, represented in Alexander disease cohorts
      by R239C and R88C, provide a variant-specific path into abnormal GFAP
      oxidation and crosslinking before aggregate and Rosenthal fiber formation.
    gene:
      preferred_term: GFAP
      term:
        id: hgnc:4235
        label: GFAP
    type: missense
    clinical_significance: PATHOGENIC
    functional_effects:
    - function: abnormal GFAP oxidation and crosslinking
      description: Cysteine-generating substitutions promote GFAP crosslinking, defective assembly, and decreased filament solubility.
    evidence:
    - reference: PMID:11567214
      reference_title: "Infantile Alexander disease: spectrum of GFAP mutations and genotype-phenotype correlation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "mutations, of which two affect arginine (2R88C and 1R88S) and two affect nonarginine residues (1L76F and 1N77Y)"
      explanation: "Clinical cohort identifies R88C as another cysteine-generating GFAP arginine substitution."
    - reference: PMID:38782207
      reference_title: "Glial fibrillary acidic protein is pathologically modified in Alexander disease."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "In vitro and cell-based studies demonstrate that cystine-generating mutations promote GFAP crosslinking by cysteine-dependent oxidation"
      explanation: "Functional evidence provides a variant-specific mechanism from cysteine-generating GFAP mutations to crosslinking and aggregation."
  evidence:
  - reference: CGGV:assertion_1da6d658-360e-4097-95a9-0b6838638e31-2024-01-10T170000.000Z
    reference_title: "GFAP / Alexander disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GFAP | HGNC:4235 | Alexander disease | MONDO:0008752 | AD | Definitive"
    explanation: ClinGen classifies the GFAP-Alexander disease gene-disease relationship as definitive with autosomal dominant inheritance.
  - reference: PMID:11138011
    reference_title: "Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alexander disease therefore represents the first example of a primary genetic disorder of astrocytes, one of the major cell types in the vertebrate CNS"
    explanation: "Landmark paper establishing GFAP mutations as causative for Alexander disease."
  - reference: PMID:21917775
    reference_title: "GFAP mutations, age at onset, and clinical subtypes in Alexander disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "R79 and R239 GFAP mutations were most common (16.6% and 20.3% of all cases, respectively). These common mutations predicted distinct clinical outcomes, with R239 predicting the most aggressive course"
    explanation: "Identifies mutation hotspots and genotype-phenotype correlations in a large cohort."
  - reference: PMID:11567214
    reference_title: "Infantile Alexander disease: spectrum of GFAP mutations and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Missense, heterozygous, de novo GFAP mutations were found in exons 1 or 4 for 14 of the 15 patients analyzed"
    explanation: "Confirms de novo missense mutations in GFAP rod domain as reliable molecular marker."
  - reference: PMID:39420046
    reference_title: "A systematic review and meta-analysis of GFAP gene variants in Alexander disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The genotype-phenotype correlation remains elusive due to the variable expressivity of clinical manifestations."
    explanation: The systematic review cautions against treating hotspot associations as deterministic because expressivity remains variable.
treatments:
- name: Supportive Care
  description: >
    Management is primarily supportive, including anti-epileptic drugs for
    seizures, physical therapy, and nutritional support. No disease-modifying
    therapy is currently approved.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301351
    reference_title: "Alexander Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment is supportive and focuses on management by multidisciplinary specialists to manage general care, feeding, and nutrition; anti-seizure medication; physical and occupational therapy; speech and language therapy; and appropriate educational services."
    explanation: GeneReviews directly supports multidisciplinary symptomatic management and the specific care domains summarized here.
- name: Zilganersen (ION373; investigational GFAP antisense oligonucleotide)
  description: >
    Antisense oligonucleotides targeting GFAP mRNA have shown efficacy in
    mouse and rat models, achieving near-complete elimination of GFAP protein
    with reversal of Rosenthal fibers, white matter deficits, and motor
    impairment. Zilganersen is being evaluated in humans, but the trial registry
    does not establish clinical efficacy.
  therapeutic_modality: ANTISENSE_OLIGONUCLEOTIDE
  aso_details:
    aso_mechanism: RNASE_H_KNOCKDOWN
    target_gene:
      preferred_term: GFAP
      term:
        id: hgnc:4235
        label: GFAP
    target_transcript: GFAP mRNA
  treatment_term:
    preferred_term: antisense oligonucleotide therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Zilganersen
      term:
        id: NCIT:C186394
        label: Zilganersen
  target_mechanisms:
  - target: Mutant GFAP Proteotoxicity
    treatment_effect: INHIBITS
    description: GFAP-targeted antisense oligonucleotides lower GFAP protein, interrupting the aggregation/Rosenthal fiber mechanism upstream of astrocyte stress and white matter injury.
    evidence:
    - reference: PMID:29226998
      reference_title: "Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Nearly complete and long-lasting elimination of GFAP occurred in brain and spinal cord following single bolus intracerebroventricular injections, with a striking reversal of Rosenthal fibers and downstream markers of microglial and other stress-related responses"
      explanation: "ASO-mediated GFAP suppression targets the upstream aggregation mechanism and reverses downstream stress markers in animal models."
  evidence:
  - reference: PMID:29226998
    reference_title: "Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Nearly complete and long-lasting elimination of GFAP occurred in brain and spinal cord following single bolus intracerebroventricular injections, with a striking reversal of Rosenthal fibers and downstream markers of microglial and other stress-related responses"
    explanation: "Antisense oligonucleotides effectively suppress GFAP and reverse pathology in AxD mouse models."
  - reference: PMID:29226998
    reference_title: "Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "GFAP protein was also cleared from cerebrospinal fluid, demonstrating its potential utility as a biomarker in future clinical applications"
    explanation: "CSF GFAP clearance provides a potential biomarker for monitoring treatment response."
  - reference: PMID:34788075
    reference_title: "Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "a single treatment with Gfap-targeted ASO provides long-lasting suppression, reverses GFAP pathology, and, depending on age of treatment, prevents or mitigates white matter deficits and motor impairment"
    explanation: "Rat model with myelin pathology demonstrates ASO therapy can both prevent and reverse disease features."
  - reference: clinicaltrials:NCT04849741
    reference_title: "A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this study is to evaluate the safety and efficacy of zilganersen (ION373) in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD."
    explanation: The registry supports ongoing human evaluation of zilganersen and its motor-function objective, not a claim of demonstrated benefit.
animal_models:
- species: Mus musculus
  genotype: Gfap R76H/+ and Gfap R236H/+ knock-in
  description: >
    Knock-in mice carrying GFAP-R76H and -R236H mutations (homologous to
    human R79H and R239H) develop Rosenthal fibers in hippocampus, corpus
    callosum, olfactory bulbs, subpial, and periventricular regions. Mice
    show elevated GFAP, white matter stress response, and increased seizure
    susceptibility but have normal lifespan, resembling adult-onset disease.
  evidence:
  - reference: PMID:17065456
    reference_title: "Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "mice with GFAP-R76H and -R236H mutations develop Rosenthal fibers, the hallmark protein aggregates observed in astrocytes in AxD, in the hippocampus, corpus callosum, olfactory bulbs, subpial, and periventricular regions"
    explanation: "Knock-in mice recapitulate Rosenthal fiber formation in disease-relevant brain regions."
  - reference: PMID:17065456
    reference_title: "Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These studies provide formal proof linking GFAP mutations with Rosenthal fibers and oxidative stress, and correlate gliosis and GFAP protein levels to the severity of the disease"
    explanation: "Provides formal proof of causality between GFAP mutations and Rosenthal fiber pathology."
- species: Rattus norvegicus
  genotype: Gfap R239H/+ knock-in
  description: >
    Knock-in rat carrying the GFAP R239H mutation exhibits hallmark
    pathology including Rosenthal fibers, widespread astrogliosis, and
    white matter deficits. Animals develop normally in early postnatal weeks
    but fail to thrive after weaning, developing severe motor deficits
    with approximately 14% dying between 6 and 12 weeks. This model
    recapitulates myelin pathology and motor impairment seen in human disease,
    unlike the milder mouse models.
  evidence:
  - reference: PMID:34788075
    reference_title: "Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we introduce a rat model of AxD that exhibits hallmark pathology with GFAP aggregation in the form of Rosenthal fibers, widespread astrogliosis, and white matter deficits"
    explanation: "Rat AxD model with clinically relevant myelin pathology and motor impairment."
  - reference: PMID:34788075
    reference_title: "Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These animals develop normally during the first postnatal weeks but fail to thrive after weaning and develop severe motor deficits as they mature, with about 14% dying of unknown cause between 6 and 12 weeks of age"
    explanation: "Characterizes the time course of disease progression in the rat model."
- species: Drosophila melanogaster
  genotype: Glial expression of human GFAP R79H and R239H
  description: >
    Transgenic Drosophila expressing disease-linked mutant human GFAP
    in fly glia develop inclusions bearing hallmarks of authentic
    Rosenthal fibers. The model demonstrates non-cell-autonomous
    neurodegeneration mediated by protein aggregation and oxidative
    stress, with neuronal apoptosis dependent on glial glutamate transport.
  evidence:
  - reference: PMID:21414908
    reference_title: "Protein misfolding and oxidative stress promote glial-mediated neurodegeneration in an Alexander disease model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We find aggregation of mutant human GFAP into inclusions bearing the hallmarks of authentic Rosenthal fibers"
    explanation: "Drosophila model recapitulates Rosenthal fiber formation from mutant human GFAP."
  - reference: PMID:21414908
    reference_title: "Protein misfolding and oxidative stress promote glial-mediated neurodegeneration in an Alexander disease model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Toxicity of mutant GFAP to glial cells induces a non-cell-autonomous stress response and subsequent apoptosis in neurons, which is dependent on glial glutamate transport"
    explanation: "Demonstrates non-cell-autonomous neurodegeneration mechanism via glutamate-dependent pathway."
clinical_trials:
- name: NCT04849741
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: >
    Intrathecal zilganersen (ION373) interventional study evaluating safety,
    pharmacokinetics, pharmacodynamics, and whether gross motor function improves
    or stabilizes. The ClinicalTrials.gov record was checked on 2026-08-04; the
    registry describes evaluation and does not report efficacy results.
  evidence:
  - reference: clinicaltrials:NCT04849741
    reference_title: "A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this study is to evaluate the safety and efficacy of zilganersen (ION373) in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD."
    explanation: The trial registry supports the investigational agent, disease population, and motor-function objective without supporting clinical efficacy.
- name: NCT02714764
  phase: NOT_APPLICABLE
  status: RECRUITING
  description: >
    Observational natural-history study collecting functional outcomes and CSF
    and blood GFAP measurements to define outcome metrics for future Alexander
    disease treatment trials. Status was checked on 2026-08-04.
  evidence:
  - reference: clinicaltrials:NCT02714764
    reference_title: "Evaluation of Outcome Metrics in Alexander Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this study is to define the natural history of Alexander Disease, a leukodystrophy that causes neurological dysfunction. Investigators will obtain clinical outcome assessments to measure how the disease affects a patient's gross motor, fine motor, speech and language function, swallowing, and quality of life. Specimens are collected to measure glial fibrillary acidic protein (GFAP) levels in cerebrospinal fluid (CSF) and blood. The data obtained from this study will be used for the design of future treatment trials."
    explanation: The registry directly supports the observational outcome domains and GFAP specimen collection used for trial-readiness research.
discussions:
- discussion_id: gap_axd_preclinical_mechanism_translation
  prompt: >
    Do STAT3 inhibition, P2Y12-dependent microglial protection, and GFAP antisense
    suppression reproduce their model-system effects in people with Alexander
    disease, and which biomarkers reliably demonstrate target engagement?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#STAT3-Driven GFAP Upregulation
  - pathophysiology#P2Y12-Dependent Protective Microglial Response
  - treatments#Zilganersen (ION373; investigational GFAP antisense oligonucleotide)
  rationale: >
    Causal STAT3 and P2Y12 evidence is presently derived from mouse models, while
    GFAP antisense reversal of pathology and functional deficits is preclinical.
    Human tissue establishes STAT3 activation and human studies establish GFAP as
    a biomarker and zilganersen as an investigational intervention, but neither
    proves that these model-derived causal effects translate into clinical benefit.
  evidence:
  - reference: PMID:37048051
    reference_title: "STAT3 Drives GFAP Accumulation and Astrocyte Pathology in a Mouse Model of Alexander Disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Astrocyte-specific Stat3 knockout in adult mice with existing pathology reversed GFAP accumulation and aggregation."
    explanation: The intervention supports STAT3 causality in mice, leaving efficacy and causal direction in human disease unresolved.
  - reference: PMID:37955589
    reference_title: "Microglia sense astrocyte dysfunction and prevent disease progression in an Alexander disease model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Clopidogrel significantly exacerbated pathological markers in AxD model mice and attenuated the morphological features of microglia, suggesting that microglia play a protective role against AxD pathology via P2Y12 receptors."
    explanation: Pharmacologic perturbation supports a protective P2Y12-dependent response in mice, not yet in people with Alexander disease.
  - reference: clinicaltrials:NCT04849741
    reference_title: "A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this study is to evaluate the safety and efficacy of zilganersen (ION373) in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD."
    explanation: The registry establishes human evaluation of zilganersen but does not provide results that resolve translation of preclinical efficacy.
datasets:
- accession: geo:GSE261158
  title: Aberrant neurodevelopment in human iPS cell-derived models of Alexander disease.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 10
  publication: PMID:39308436
  notes: Identified by GEO DataSets index search for Alexander Disease (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE116327
  title: Gene expression changes associated with Alexander disease (AxD)
  description: We use human induced pluripotent stem cell (hiPSC)-derived astrocytes and post-mortem human brain tissues to study gene expression changes associated with AxD
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 12
  notes: Identified by GEO DataSets index search for Alexander Disease (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
references:
- reference: PMID:20301351
  title: Alexander Disease.
  tags:
  - GeneReviews
- reference: PMID:11138011
  title: Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease.
- reference: PMID:21917775
  title: GFAP mutations, age at onset, and clinical subtypes in Alexander disease.
- reference: PMID:21533827
  title: Nationwide survey of Alexander disease in Japan and proposed new guidelines for diagnosis.
- reference: PMID:29226998
  title: Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease.
- reference: PMID:37048051
  title: STAT3 Drives GFAP Accumulation and Astrocyte Pathology in a Mouse Model of Alexander Disease.
  found_in:
  - Alexander_Disease-deep-research-falcon.md
- reference: PMID:37920915
  title: Acquisition and Loss of Developmental Milestones and Time to Disease-Related Outcomes in Cerebral Alexander Disease.
- reference: PMID:37955589
  title: Microglia sense astrocyte dysfunction and prevent disease progression in an Alexander disease model.
  found_in:
  - Alexander_Disease-deep-research-falcon.md
- reference: PMID:38558318
  title: Plasma concentrations of glial fibrillary acidic protein, neurofilament light, and tau in Alexander disease.
  found_in:
  - Alexander_Disease-deep-research-falcon.md
- reference: PMID:39420046
  title: A systematic review and meta-analysis of GFAP gene variants in Alexander disease.
  found_in:
  - Alexander_Disease-deep-research-falcon.md
- reference: PMID:40520824
  title: Genotype-Phenotype Association for 14 GFAP Variants in Alexander Disease.
- reference: PMID:41513585
  title: Characterization of Clinical Phenotype to Glial Fibrillary Acidic Protein Concentrations in Alexander Disease.
  found_in:
  - Alexander_Disease-deep-research-falcon.md
- reference: PMID:41581419
  title: "Natural History and Prognostic Factors in Pediatric Alexander Disease: A Cohort Study."
- reference: PMID:41830670
  title: Alexander disease mutations differentially sensitize glial fibrillary acidic protein (GFAP) to posttranslational modifications and network disruption by oxidants.
- reference: clinicaltrials:NCT04849741
  title: A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease
- reference: clinicaltrials:NCT02714764
  title: Evaluation of Outcome Metrics in Alexander Disease

📚

References & Deep Research